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Abstract 
Experimental Lyme arthritis is induced by the infection of C3H mice with the 
spirochete, Borrelia burgdorferi, and is a valuable model to study the regulation 
of inflammation during bacterial infection. While the lab has previously focused 
on how inflammation is initiated, this thesis focuses on the role of apoptotic cells 
during inflammation resolution in Lyme arthritis. We show administration of 
apoptotic cells can be used to initiate earlier resolution in B. burgdorferi-infected 
mice by decreased neutrophil recruitment, and this may be due to increased 
PPAR-γ activation. Additionally, the PPAR-γ agonist, rosiglitazone, can be used 
as a cell-free treatment to elicit a similar effect as the apoptotic cells. We also 
define the role of various eicosanoids during inflammation resolution. If apoptosis 
or efferocytosis, the phagocytosis of apoptotic cells, is dysregulated, it can cause 
exacerbated inflammation and arthritis. BLT1-/- neutrophils have a defect in 
apoptosis and efferocytosis recognition to due decreased DISC formation. This is 
a result of increased cAMP in BLT1-/- neutrophils due to the inability for 
LTB4/BLT1 signaling to downregulate cAMP. Additionally, macrophages must be 
able to produce PGE2 to be affected by and efferocytose apoptotic cells 
efficiently. Deficiencies in either of these eicosanoid signaling pathways results in 
increased cellular infiltrate during arthritis resolution, prolonging inflammation. 
We also show apoptotic cells actively secrete mediators to aid in their alteration 
of the inflammatory response. These results demonstrate the importance of 
apoptosis and efferocytosis during inflammation resolution in Lyme arthritis and 
several mechanisms involved. 
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Chapter 1 
Introduction 
 
Inflammation 
Inflammation is a protective reaction of the microcirculation initiated after an 
infection or injury [1]. Local and systemic inflammatory responses are activated 
to aid in the elimination of the stimulus, promote tissue repair, and establish 
immune memory during an infection. The acute inflammatory response involves 
the production and signaling of soluble mediators, including cytokines, 
chemokines, and eicosanoids by resident immune cells, including macrophages 
and fibroblasts already residing within the tissue [2, 3]. Additionally, cell adhesion 
molecules on circulating leukocytes are upregulated and promote an influx of 
granulocytes from the blood [1]. Upon arrival to the site of infection or injury, the 
granulocytes, primarily neutrophils, perform their primary function to phagocytose 
and eliminate microbes or tissue debris [1].  
 
Inflammation resolution 
Inflammation resolution is defined as the time between peak inflammatory cell 
influx and the clearance of these cells from the tissue site and restoration of 
homeostasis [4]. The recruited immune cells undergo apoptosis, while phagocytic 
cells, macrophages and dendritic cells, are able to phagocytose the apoptotic 
cells by efferocytosis, the phagocytosis of apoptotic cells [5]. This process was 
once thought to be passive, but increasing evidence suggest the efferocytosis of 
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apoptotic cells plays a role in inflammation resolution [3, 5, 6]. Not only can 
efferocytosis have a negative regulation of pro-inflammatory nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) signaling [7] and Toll-like 
receptor (TLR)4 expression [8], it can also increase pro-resolution signaling of 
peroxisome proliferator-activated receptor (PPAR)-γ [5, 6] and prostaglandin 
(PG)E2 [9]. Today, many anti-inflammatory therapies are based upon inhibiting 
the factors responsible for driving inflammation to help combat pro-inflammatory 
signaling, however, this may treat the symptoms, rather than causing resolution. 
In addition, this limits the host’s immune response, leaving treated individuals 
vulnerable to microbial infection. New therapeutic strategies are focusing on 
inhibiting pathways that breakdown pro-resolution mediators or activate pro-
resolving mediators [1]. 
 
Non-resolving inflammation 
While inflammation is important during a response to injury or a pathogen, failure 
to resolve inflammation can cause deleterious effects to the surrounding tissue 
and further immune responses. The acute inflammatory response can be divided 
into three phases: the productive phase, the transition phase, and the resolving 
phase. The productive phase involves cellular recruitment by increasing blood 
flow to the site of injury or infection [10]. The transition phase allows for recruited 
neutrophils and macrophages to perform their function, while the resolving phase 
returns the inflamed tissue back to homeostasis [11]. If cellular infiltration 
remains past their function in acute inflammation, chronic inflammation can 
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occur. Chronic, or non-resolving inflammation is associated with tissue 
degeneration mediated by nitrogen species, lipids, cytokines, proteases, and 
reactive oxygen species produced by inflammatory cells [12]. No single 
phenomenon contributes more to the medical burden in modern society than 
non-resolving inflammation [13].  
 
Non-resolving inflammation is not the primary cause of diseases such as obesity, 
atherosclerosis, cancer, asthma, neurodegenerative disease, multiple sclerosis 
or rheumatoid arthritis, but it contributes significantly to their pathogenesis [13]. 
Non-resolution can also occur during persistent infections. Chronic inflammation 
associated with tuberculosis can persist for decades, and when inflammation is 
extensive enough can cause severe lung damage and death [13]. The continual 
recruitment of immune cells, or if infiltrating immune cells fail to undergo 
apoptosis to limit their pro-inflammatory responses can cause further 
inflammation during an immune response. In addition, the inability to clear 
apoptotic infiltrating immune cells in a timely manner also contributes to chronic 
inflammation. Therefore, understanding apoptosis and the clearance of apoptotic 
cells is important to understand non-resolving inflammation, which contributes to 
a wide variety of diseases. 
 
Apoptosis and other forms of cell death 
Apoptosis, or programmed cell death, is a crucial mechanism responsible for 
normal cell turnover, tissue sculpting during embryogenesis, immune system 
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development, and damaged cell removal [14, 15]. Cells undergoing apoptosis will 
shrink without compromising the plasma membrane integrity, along with nuclear 
condensation and fragmentation, and bleb off into smaller pieces called apoptotic 
bodies [16]. Apoptotic cells and apoptotic bodies are then quickly taken up by 
efferocytosis, the phagocytosis of apoptotic cells, by professional phagocytes, 
including macrophages and dendritic cells [17]. Apoptosis is mediated by a set of 
caspases, which ultimately activate pro-caspase-3 into its active form, caspase-
3. Caspase-3 is an executioner caspase involved in apoptosis, and is responsible 
for chromatin condensation, nuclear fragmentation, and cytoskeletal degradation, 
making active caspase-3 a useful marker for the detection of apoptotic cells [18]. 
Regardless of how apoptosis is induced, all apoptotic cells have similar physical 
properties. During apoptosis, phosphatidylserine (PS), normally found on the 
inside of the cell membrane, is exposed on the outer cell surface. This is 
accomplished by a caspase-3-dependent flippase and scramblase activity which 
translocates phosphatidylserine to the external portion of the cellular membrane 
[19, 20].  
 
Apoptosis differs from other forms of cell death, including necrosis, pyroptosis, 
and NETosis, in that they can cause an inflammatory response. During necrosis, 
the cells will swell, nuclear DNA will clump up or degrade, plasma membranes 
rupture, and cellular components are released [16]. Cells become necrotic due to 
changes in physiological conditions, including hypoxia, toxin exposure, exposure 
to reactive oxygen species, extreme temperature changes, and nutrient 
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depravation [21]. Necrosis is a passive, unregulated cell death, however, 
necroptosis is a regulated active type of cell death [22]. Necroptosis is induced 
by the death receptor ligand tumor necrosis factor (TNF), and the kinases, 
receptor-interacting protein kinases (RIPK)1 and RIPK3, are involved in TNF-
induced necroptosis [23]. RIPK1 and RIPK3 are involved in formation of the 
necrosome, a complex responsible for the induction of necroptosis [24]. 
Activation of this complex causes production of reactive oxygen species and 
rapid depletion of cellular adenosine triphosphate (ATP), causing mitochondrial 
dysfunction and subsequent cell death [25]. 
 
Pyroptosis is a caspase-dependent form of inflammatory cell death that depends 
on the activation of either caspase-1 or caspase-11 [26, 27]. Caspase-1 is 
responsible for the cleavage of pro-IL-1β and pro-IL-18 into their active pro-
inflammatory cytokine forms of IL-1β and IL-18, respectively [14]. Cells 
undergoing pyroptosis form a caspase-1 dependent plasma membrane pore, 
causing a disruption in cellular ionic gradients, increasing osmotic pressure and 
water influx [28]. This causes the cell to swell and eventually lyse, releasing pro-
inflammatory cellular contents [29]. Additionally, an unidentified caspase-1-
activated nuclease is responsible for DNA cleavage during pyroptosis. 
 
NETosis is a specific form of neutrophil cell death in which neutrophil extra-
cellular traps (NETs) are released [30]. NETs are large extracellular structures 
composed of decondensed chromatin that provide a physical barrier to prevent 
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microbial escape and recruit anti-microbial effectors [31]. Unlike apoptosis, both 
the nuclear and granular membranes disintegrate during NETosis, while 
maintaining plasma membrane integrity [32]. Also, activation of caspases does 
not occur during NETosis [33].  While NETs can aid in bacterial removal, they 
also cause a robust inflammatory response. Extracellular neutrophil elastase 
released by NETosis is responsible for lung tissue damage and cystic fibrosis 
progression [34]. 
 
Forms of apoptosis 
Apoptosis can be initiated by two different pathways, intrinsic and extrinsic 
(Figure 1). Intrinsic apoptosis, also called mitochondrial-mediated apoptosis, is 
activated by a range of exogenous and endogenous stimuli, including DNA 
damage, ischemia, and oxidative stress. This form of apoptosis plays a role in 
the elimination of damaged cells [35]. The B cell lymphoma (Bcl)-2 family of 
proteins located on the mitochondrial membrane regulate apoptosis by the 
expression of pro-apoptotic mediators, like Bax and Bak, and anti-apoptotic 
mediators, including Bcl-2 and myeloid cell leukemia (Mcl)-1 [16]. During pro-
apoptotic signaling, the mitochondrial membrane is perturbed, and cytochrome C 
is released into the cytoplasm, where it forms a complex with apoptotic protease 
activating factor 1 (APAF1) and pro-caspase-9 [35]. The complex cleaves pro-
caspase-9 into its active form, which then cleaves and activates caspase-3 [36].  
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Figure 1: Intrinsic and extrinsic apoptosis pathways. 
Intrinsic apoptosis is initiated through the mitochondria and activates caspase 9. 
Caspase 9 in turn cleaves pro-caspase 3 into its active form. The active cleaved-
caspase 3 initiates apoptosis. Alternatively, extrinsic apoptosis is initiated through 
Fas/FasL interaction. This activates pro-caspase 8 into its active form. If there is 
a strong signal of caspase 8, it will cleave pro-caspase 3 directly, or if the 
caspase 8 signal is weak, it will signal through the mitochondria and then follow 
the intrinsic apoptosis pathway.  
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Extrinsic apoptosis is triggered by the TNF family of death receptors, Fas ligand 
(FasL), TNF-α, and TNF-related apoptosis-inducing ligand (TRAIL) [37]. Their 
cytoplasmic regions contain a region called the death domain that is required for 
apoptosis signaling [38]. The activated death domain recruits  
Fas-associated protein with death domain (FADD), pro-caspase-8, and cellular 
FLICE/caspase 8 inhibitory proteins (c-FLIP) [38]. The complex consisting of Fas, 
FADD, pro-caspase-8, and c-FLIP is called the death-inducing signaling complex 
(DISC) [39]. After formation of the DISC, apoptosis can be signaled in two 
different ways. In cells where caspase-8 is strongly or sufficiently activated at the 
DISC, caspase-8 directly activates pro-caspase-3 into its active form. In cells 
where caspase 8 is not strongly activated, caspase-8 will cleave Bid, another 
member of the Bcl-2 family, and the cleaved Bid will induce cytochrome C 
release from the mitochondria into the cytoplasm [37, 38]. Cytochrome C then 
actives the intrinsic caspase-9/caspase-3 apoptosis pathway [35]. 
 
Efferocytosis 
Efferocytosis, can be broken down into four major steps [40]. First, apoptotic cells 
release “find me” signals to attract phagocytic cells to the location of the 
apoptotic cells [41]. Next, the apoptotic cell is taken up by recognition of its “eat 
me” signals or is not engulfed due to its expression of “do not eat me” signals 
[42]. During the third step the apoptotic cell is ingested by the phagocytic cell and 
degraded within the phagolysosome. Lastly, the post-engulfment consequences 
of efferocytosis, including release of anti-inflammatory cytokines and other 
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mediators by the phagocyte, occur following degradation of the apoptotic cell 
[43].  
 
During early apoptosis, apoptotic cells release “find me” signals, either as soluble 
molecules or as a part of complex extracellular vesicles [44]. “Find me” signals 
include: chemokines CX3CL1 and IL-8, nucleotides ATP and UTP, lipids lyso-, 
such as, phosphatidylcholine and sphingosine-1-phosphate (S1P), and the 
extracellular vesicle component, intercellular adhesion molecules (ICAM)-3 [45]. 
It is currently thought these “find me” signals only act over a short range, due to 
their short half-life due to degradation [46]. “Find me” signals are also postulated 
to regulate engulfment components in the recruited phagocytes and influence 
immunogenic vs non-immunogenic responses to apoptotic cells [47]. Cells can 
also release “keep out” signals, such as lactoferrin, to deter recruitment of 
phagocytic cells [45]. 
 
The specific recognition of dying cells among live cells depends on the 
identification of apoptotic cells by a class of “eat me” signals. The most well 
characterized “eat me” signal is PS, which trans-locates to the outside of the cell 
during apoptosis. PS is directly recognized by several receptors, including T cell 
immunoglobulin mucin-1 (TIM-1), TIM-4, and receptor for advanced glycation 
endproducts (RAGE) [45]. All these receptors are not ubiquitously expressed, 
however, therefore phagocytic cells will have variable expression of these 
receptors [44]. Additionally, these receptors do not bind to PS with the same 
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affinity or avidity. Other “eat me” signals include annexin I and ICAM-3, which is 
also a “find me” signal [45]. PS can also be modified by oxidation, which allows 
for additional further recognition by phagocytic cells via scavenger receptors, 
such as CD36, CD68, and LOX-1 [48-50]. Calreticulin, which is upregulated 
during apoptosis, can also be recognized by the phagocytic receptor CD91 (LDL-
receptor-related protein) [51]. Even in the presence of PS, there are still “don’t 
eat me” signals that can prevent apoptotic cell recognition, including CD300a, 
CD31, and CD47. CD300a inhibits apoptotic cell engulfment by competitive 
phospholipid binding on apoptotic cells [52]. CD31 prevents ingestion of viable 
cells, but has an altered function when disabled [53]. CD47 inhibits apoptosis via 
SIRPα, and apoptosis clearance only occurs with its disruption [51].  
 
Following the initial contact and recognition between the phagocytic and 
apoptotic cell, tethering of the cells can occur to prevent detachment of the 
apoptotic cell. TIM-4, disabled CD31, and CD14 are all involved in the tethering 
process [53, 54]. After engulfment, the phagosome becomes acidic and fuses 
with the phagolysosome, resulting in degradation of the apoptotic cell [55]. This 
stimulates the phagocytic cell to release anti-inflammatory mediators, such as IL-
10, TGF-β, and PGE2, while suppressing released pro-inflammatory cytokines 
TNF-α, IL-1, IL-12, and IL-8 [6, 56, 57]. 
 
 If there is a breakdown during any process of efferocytosis, the result can be 
chronic inflammation. If inflammatory cells, such as neutrophils, fail to undergo 
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apoptosis, their inflammatory effector functions of producing pro-inflammatory 
cytokines and recruiting additional immune cells to the site of inflammation can 
be prolonged, driving further inflammation [43]. Additionally, if there is a 
breakdown in phagocytic cell recruitment to apoptotic cells, recognition of 
apoptotic cells by phagocytes, or the phagocytosis of apoptotic cells, then the 
apoptotic cells can undergo a secondary necrosis, furthering the inflammatory 
response [43]. Not only is apoptosis important for limiting inflammatory 
responses, but the prompt clearance of apoptotic cells contributes to the 
prevention of further inflammatory responses.  
 
Apoptosis during bacterial infection 
The process of apoptosis can be altered by bacteria to increase their 
pathogenicity. By blocking or delaying cell death, bacteria can promote their own 
intracellular replication and survival. For example, Legionella pneumophila 
replicates within alveolar macrophages, where the pathogen can deliver 
effectors, including Sdha and SidF, by its type IV secretion system to delay cell 
death. Sdha inhibits mitochondrial disruption and caspase activation of intrinsic 
apoptosis [58]. SidF also inhibits mitochondrial-mediated apoptosis by targeting 
BNIP3 and Bcl-rambo [59]. Anaplasma phagocytophilym infects neutrophils and 
limits apoptosis by preventing the loss of mitochondrial membrane potential, 
blocking the intrinsic apoptosis pathway [60]. Helicobacter pylori can block both 
intrinsic and extrinsic apoptosis, by upregulating pro-survival ERK signaling and 
Mcl-1, an anti-apoptotic factor, to aid in persistent colonization of the stomach 
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mucosa [61]. Mycobacterium tuberculosis uses a two-step strategy in regulating 
host apoptosis. Early in infection, the pathogen post-pones cell death by 
upregulation of FLIP, an inhibitor of death receptor signaling, while later during 
infection promotes apoptosis and cell death in order to promote infection of other 
cells [62]. 
 
Apoptosis during viral infection 
Viruses can also alter apoptosis of host cells to increase viral pathogenesis. 
Respiratory syncytial virus (RSV) inhibits neutrophil apoptosis by increasing 
expression of the anti-apoptotic Mcl-1 protein and NF-κB signaling [63]. Human 
cytomegalovirus (HCMV)-infected neutrophils increase their expression of 
extracellular adhesion molecules and ROS production to prolong inflammation, 
and in addition, inhibit caspase-8 by viral protein UL36 to prevent Fas-ligand-
mediated apoptosis [64]. During HIV/SIV infection, the frequency of neutrophil 
apoptosis is correlated to disease severity. Neutrophil apoptosis increases when 
CD4 T cell numbers decrease, and introduction of retro-viral therapies reduces 
neutrophil apoptosis [65, 66]. Influenza A virus also accelerates neutrophil 
apoptosis through increased expression of Fas/FasL and oxidative stressors [67]. 
The increase in neutrophil apoptosis may also contribute to impairment of 
protection against secondary bacterial infections often associated with these 
diseases. 
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Apoptosis dysregulation 
Dysregulation of apoptosis is thought to lead to several diseases with either too 
much or too little apoptosis, and may contribute to nearly half of all human 
diseases [68]. Autoimmune lymphoproliferative syndrome (ALPS) is the result of 
CD95 dysfunction [69]. During this disease, the immune system is unable to 
eliminate self-reactive lymphocytes by apoptosis and results in auto-immunity 
[69]. Patients with Systemic Lupus Erythematosis (SLE) have a defect in the 
clearance of apoptotic cells displaying autoantigens on their cell surface. This 
prevents the elimination of autoreactive T and B cells, resulting in tissue 
destruction [70]. The failed clearance of apoptotic cells also contributes to 
prolonged inflammatory responses during chronic obstructive pulmonary disease 
(COPD), pulmonary fibrosis, and cystic fibrosis [71]. Increased elastase cleavage 
of CD14 on the surface of macrophages contributes to reduced engulfment of 
macrophages in these diseases [72]. Apoptosis is induced in spinocerebellar 
ataxia types 1 and 3 in Huntington’s disease patients, driven by increased 
caspase 3 expression from the Huntington protein [73]. In amyotrophic lateral 
sclerosis (ALS) patients, mutations causing an increase in caspase-3 expression, 
leads to motor neuron apoptosis [74]. Finally, most cancer cells contain changes 
or mutations in genes that regulate apoptosis, leading to excessive proliferation 
and decreased apoptosis or apoptosis resistance [75]. 
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Therapeutic potential of apoptotic cells 
Since apoptosis and efferocytosis play a role in the downregulation of 
inflammation and the anti-inflammatory nature of apoptotic cells, it has been 
proposed to utilize apoptotic cells as a potential therapeutic for the treatment of 
chronic inflammatory disease [76].  In streptococcal-cell wall induced arthritis, a 
model for rheumatoid arthritis, an injection of apoptotic cells was able to reduce 
the severity of disease by increasing levels of T regulatory cells [77]. In an 
inflammatory model of lung fibrosis, an instillation of apoptotic cells within the 
lung promoted inflammation resolution and a more positive disease outcome [5]. 
Additionally, therapeutics have been developed by utilizing apoptotic signaling 
pathways to treat diseases where apoptosis is known to be dysregulated. 
CD95/CD95L has been used to treat multiple sclerosis [78], and Bcl-2 proteins 
have been targeted for breast cancer, leukemia, and Non-Hodgkins lymphoma 
treatment [79]. Further characterization of the apoptotic pathway and how 
apoptosis and efferocytosis contributes to inflammation resolution will aid in the 
development of future therapeutics. 
 
Lyme Disease 
Lyme Disease is the most prevalent vector-borne disease in the United States 
with an estimated 300,000 new cases each year [80]. The etiological agent of 
Lyme Disease, Borrelia burgdorferi, is a spirochete and is transmitted to humans 
and animals through the bite of infected Ixodes ticks. Ixodes scapularis ticks are 
the primary vectors of Lyme Disease and are found in the Eastern and Central 
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United States, and in addition, Ixodes pacificus ticks are located in the Western 
United States [81]. While the majority of Lyme Disease cases are reported from 
the New England and upper Midwestern states, the expansion of the 
geographical range of the Ixodes ticks has contributed to a 25-fold increase in 
cases in humans since 1982 [80, 82]. Currently, there is no vaccine available for 
Lyme Disease prevention in humans [83]. 
 
B. burgdorferi transmission 
During the enzootic cycle of B. burgdorferi, Ixodes ticks undergo a three-stage 
life cycling, larva, nymph, and adult, to which a bloodmeal is taken at each of 
these stages (Figure 2) [84]. B. burgdorferi cannot be passed via transovarial 
transmission, from adult to egg, so each generation of tick must acquire B. 
burgdorferi after hatching [85]. Larval ticks feed on many different animals, 
including birds, mice, and squirrels, and B. burgdorferi is acquired through the 
bloodmeal from an infected animal. The tick will remain infected with B. 
burgdorferi for the remainder of its life [84]. Following the first bloodmeal, larval 
ticks will molt into the nymph stage and feed on its second host, which includes a 
similar range of animals as in the larval stage. Infected nymphal ticks can now 
transmit B. burgdorferi to new hosts, and nymphal ticks are the primary 
transmitter of B. burgdorferi to humans and companion animals, who are 
considered dead end or incidental hosts [85]. Shortly after the second bloodmeal, 
the tick will molt again into the adult stage. Adult ticks are not critical for 
maintaining B. burgdorferi in the wild due to the fact they mainly feed on larger  
 16 | P a g e  
 
 
 
 
 
 
Figure 2: B. burgdorferi transmission cycle. 
Adult female ticks will lay eggs, and the eggs will hatch into spirochete free 
larvae. Larva will feed on small animals for their first bloodmeal and will become 
infected if they feed on spirochete infected animals. Larva will then drop from the 
host and molt into nymph stage ticks. Infected nymph ticks will infect additional 
animals or incidental or dead-end hosts, including humans and dogs. This is the 
most common size of tick that transmits Lyme to humans. After their second 
bloodmeal, nymphs drop from their host and will molt into adult ticks. This stage 
of tick continues to feed on larger animals, including deer, for the remainder of 
their life.  
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animals like deer, which are incompetent hosts for the spirochete [85]. Deer are 
important, however, for maintaining the tick population as, adult ticks mate on 
them [84]. 
 
B. burgdorferi pathogenesis 
 B. burgdorferi pathogenesis is determined by its expression of various outer 
surface proteins (Osps). While OspA is required for adherence in the tick midgut, 
its expression decreases upon leaving the midgut and injection into a mammalian 
host [86]. Meanwhile, OspC expression increases during tick transmission and is 
thought to play a role in the migration and survival of the spirochete [86]. Once 
transmitted into the host, B. burgdorferi replicate within the skin near the site of 
transmission for a short time before migrating throughout the entire body. 
Spirochetes will localize in various tissues throughout the body, including the 
joints and heart in humans [87] and the kidneys in dogs [88]. Nearly 80%-90% of 
infected humans will develop a bull’s eye rash, called erythema migrans, around 
the site of transmission accompanied by mild flu-like symptoms [89]. Upon 
diagnosis, doxycycline or amoxicillin are prescribed to combat spirochete growth 
and to prevent more advanced symptom development [90]. Prompt treatment is 
critical as B. burgdorferi spread occurs rapidly within the host [87]. Around 60% 
of individuals which do not receive prompt antibiotic treatment, develop 
debilitating long-term complications, including chronic fatigue, neurological 
problems, carditis, and chronic arthritis [80, 91]. B. burgdorferi has been shown 
to form antibiotic resistant persister cells after initial antibiotic treatment, which 
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could contribute to the rise in antibiotic resistant strains found in humans and an 
increase in chronic Lyme symptom prevalence in treated individuals [92].  
 
Lyme arthritis 
Lyme arthritis in humans can be severe and is characterized by an increase in 
inflammatory cell infiltrate, usually within the weight-bearing joints of the knees 
and ankles, and subsequent tendonitis [93]. In the murine model of experimental 
Lyme arthritis, arthritis-susceptible C3H/He (C3H) are infected with B. burgdorferi 
via the foot-pad injection in each of the hind legs, which results in swelling of the 
ankle joints, peaking around 3 – 4 weeks post-infection [94]. C3H mice are 
susceptible as they develop disease, however, C57BL/6 and DBA/2 mice are 
resistant and display minimal inflammation [95]. Greater susceptibility to Lyme 
arthritis in the C3H mouse strain is not due to increased infection, as spirochete 
clearance is similar between susceptible and resistant strains [96]. This model 
recapitulates a portion of the disease found in infected Lyme patients, and 
disease pathogenesis correlates between Lyme disease patients and this 
experimental mouse model [97]. 
 
 Lyme arthritis development as studied in mice is mediated by innate immune 
cells [98], because mice without the adaptive T and B cells remain susceptible 
[99]. Development of arthritis correlates with KC/CXCR2-mediated recruitment of 
neutrophils into the infected joint, followed closely by inflammatory monocytes [2, 
100]. A variety of pro-inflammatory mediators contribute to arthritis induction, as 
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blocking these mediators resulted in decreased severity of disease [101-103]. 
While antibody-mediated clearance of B. burgdorferi from the infected joints is 
likely to play a role during inflammation resolution [94], the inhibition of several 
immune pathways resulted in poor arthritis resolution despite normal B. 
burgdorferi antibody production [3, 98, 104]. The mechanism by which 
inflammation resolution occurs in Lyme arthritis is currently unknown.  
 
Eicosanoids and Lyme arthritis 
Eicosanoids are locally acting bioactive signaling lipids derived from arachidonic 
acid (AA) and are related to polyunsaturated fatty acids (PUFA) that regulate a 
variety of inflammatory processes [105]. AA is released from the cellular 
membrane upon immune cell activation and is then metabolized into various 
bioactive lipids by three enzymatic pathways: lipoxygenase (LO), 
cyclooxygenase (COX), and cytochrome P450 (CYTP) [106]. The LO pathway is 
responsible for the production of pro-inflammatory leukotrienes and the pro-
resolving lipoxins [3]. Leukotrienes are important for neutrophil recruitment and 
promote bronchoconstriction during airway inflammation. Lipoxins are pro-
resolving mediators that aid in returning tissue homeostasis after an inflammatory 
event [4]. The COX pathway is responsible for the synthesis of the 
prostaglandins (PG) and thromboxanes (TX). These lipids are responsible for 
promoting the cardinal signs of inflammation, redness, pain, heat, and swelling, 
and many anti-inflammatory drugs are inhibitors of COX inhibitors, including 
aspirin and ibuprofen [104, 106]. The CYTP pathway produces EETs, 
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responsible for vasodilation, angiogenesis, and cellular proliferation during an 
infection [105]. 
 
The prostaglandin PGE2 has been previously only thought of as pro-
inflammatory, as it seems to be an important driver of rheumatoid arthritis, 
however, more recent studies have determined PGE2 can either be pro- or anti-
inflammatory depending on which of its receptors is utilized [107]. This 
corresponds to upregulation of PGE2 within the joints during arthritis induction 
and resolution during Lyme arthritis as determined by lipidomics [108]. 
Additionally, both COX-2-/- [104] and  5- lipoxygenase (5-LO)-/- mice fail to resolve 
during Lyme arthritis, characterized by increased cellular infiltrate during 
resolution and decreased efferocytosis of apoptotic neutrophils by macrophages 
in 5-LO-/- mice [3]. This suggests that while both pathways are responsible for 
pro-inflammatory mediators, they also have a secondary role during inflammation 
resolution. Defining the dual role of these lipid mediators during Lyme arthritis 
resolution will aid in a better understanding of how inflammation resolution is 
initiated and regulated. 
 
Purpose and experimental approach 
While much is known about how inflammation is induced in the Lyme arthritis 
model, very little is known how the resolution of inflammation occurs. Human 
Lyme arthritis patients develop a recurring, remittent arthritis with symptoms that 
may last for months. Lyme arthritis is an inflammatory arthritis model in which 
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disease develops and then undergoes spontaneous resolution. Therefore, 
mechanisms of disease development and resolution can be studied in a single 
system using a relevant infectious organism. Understanding how inflammation 
resolution is initiated and the signals involved is of utmost importance for the 
future development of therapeutics for chronic inflammatory diseases. This 
research focuses on apoptotic cells and understanding their role in inflammation 
resolution during experimental Lyme arthritis.  
 
The first research focus describes how administration of apoptotic cells in mice 
infected with B. burgdorferi promotes earlier resolution of inflammation via 
activation of PPAR-γ, showcasing how understanding the role of apoptotic cells 
can lead to potential therapeutics for inflammatory disease. The second set of 
data shows the importance of the pro-inflammatory eicosanoid LTB4 and its high-
affinity receptor BLT1 in signaling apoptosis and how the lack of these signals 
can lead to exacerbated inflammation and disease. Subsequent data showcases 
other important aspects of apoptotic cells, including their secretory products and 
their activation state prior to apoptosis. Additionally, the role of PGE2 is accessed 
during Lyme arthritis resolution.  
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Chapter 2 
Materials and Methods 
 
Mouse strains 
C3H/HeJ mice, 4-6 weeks of age were used as the wild type (WT) mice for all 
experiments. Additionally, breeding pairs of BLT1-/- (B6.129S4-Ltb4r1tm1Ald/J) 
(Jackson Laboratory) and mPGEs-1-/- on a C57BL/6 background were 
backcrossed for 10 generations onto a C3H/HeJ background for some 
experiments. Both males and females were used for in vivo experiments and as 
a source of bone marrow cells. The mice were bred and housed in a specific 
pathogen-free facility and given continuous access to food and water. At specific 
time points following infection, mice were humanely euthanized via CO2 
inhalation as accepted by American Veterinary Medical Association guidelines. 
All studies were conducted in accordance with the guidelines of ACUC of the 
University of Missouri and performed under an approved protocol.  
 
Bacteria and infections 
Spirochetes from the N40 strain of B. burgdorferi were used for all infections 
[109]. Frozen stocks stored at -80°C were added to 7ml of complete Barbour-
Stoenner-Kelly-H medium containing 6% rabbit serum (Sigma) and grown for 6 
days to log phase at 32°C. Spirochetes were enumerated using dark-field 
microscopy and a Petroff-Hausser counting chamber (Hausser Scientific, 
Horsham, PA). For all in vivo infections, dilutions were made in sterile Barbour-
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Stoenner-Kelly-H medium so that each hind footpad was inoculated with 50 µl of 
medium containing 5 x 104 B. burgdorferi. GFP-expressing B. burgdorferi (a kind 
gift from J. Carroll [110], NIH), was used for all phagocytosis assays. B. 
burgdorferi was given at a multiplicity of infection (MOI) of 10 for all in vitro 
studies.  
 
Assessment of arthritis pathology 
Progression of the arthritis was monitored by measuring the ankle swelling of the 
thickest cranio-caudal portion of the joint by use of a metric caliper. The increase 
in diameter of the ankle was determined by measuring the joint one day prior to 
infection and subtracting this value from the measurement post-infection. Ankles 
were harvested on indicated days and fixed in 10% zinc-formalin, paraffin 
embedded and stained with hematoxylin and eosin. Sections were evaluated in a 
blinded manner for disease severity on scale of 0 to 4, with 0 representing no 
inflammation and 4 representing severe inflammation, as previously described 
[2]. 
 
Determination of tissue B. burgdorferi loads 
Ankles were harvested and snap-frozen in liquid nitrogen and homogenized in 
TRIzol reagent according to the manufacturer’s protocol. Multiplex real-time PCR 
was performed using SYBR Green PCR Master Mix (Applied Biosystems) 
according to the manufacturer’s instructions. Reactions for B. burgdorferi flagellin 
were normalized to copies of nidogen DNA within the same sample, as 
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previously described [100]. Bacterial loads are expressed as copies of B. 
burgdorferi flagellin per 1000 copies of mouse nidogen [2]. 
 
Isolation of bone marrow-derived macrophages 
Bone marrow was isolated from mouse tibias and femurs by flushing the bones 
with sterile Hank’s Balanced Salt Solution (HBSS) (Life Technologies) containing 
2% fetal bovine serum (FBS) (Sigma). Isolated bone marrow was cultured for 6 
days in RPMI 1640 supplemented with 30% L929 cell-conditioned medium, 10% 
FBS, and 2% penicillin-streptomycin (Life Technologies) at 37°C in 5% CO2. 
Adherent cells were scraped, washed, plated, and left overnight at 37°C in 5% 
CO2 in RPMI 1640 supplemented with 10% FBS and 2% penicillin-streptomycin. 
 
Neutrophil extraction 
Neutrophils were isolated as previously described [2]. Briefly, bone marrow was 
harvested as stated above from mouse tibias and femurs and separated on a 1-
ml Histopaqe-1119 and 5-ml Histopaque-1038 (Sigma) gradient at 700 x g for 30 
minutes at room temperature (RT). ACK lysis buffer was added to the last 1.5 ml 
of the gradient, incubated for 3 minutes at RT, and spun down at 500 x g for 5 
minutes. For CFSE-labeled neutrophils, the CellTrace Far Red Cell Proliferation 
Kit (Thermo Fisher) was used according to the manufacturer’s instructions.  
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Apoptotic cells 
For indicated experiments, Jurkat cells were grown in complete media containing 
RPMI 1640, 10% FBS, and 2% penicillin-streptomycin at 37°C in 5% CO2 until 
needed. Jurkat cells were pelleted at 300 x g at 4°C for 5 minutes, and the 
supernatant was discarded. Cells were resuspended in complete media and 
washed three times. Cells were resuspended in 1 ml of RPMI 1640 containing 
10% FBS and CD95 Fas Ab (Biolegend) at 10 µl/ml. After 6 hours, cells were 
counted and diluted to a concentration of 1 x 106 apoptotic cells (AC)/ml. Ten 
microliters was injected into the tibio-tarsal joint synovial cavities of each mouse 
on indicated days for in vivo experiments. For apoptotic neutrophils, bone 
marrow neutrophils (BMN) were harvested as described above and left for 24 
hours in complete media containing RPMI 1640, 10% FBS, and 2% penicillin-
streptomycin at 37°C in 5% CO2. AC were verified via flow cytometry by cleaved-
caspase 3+ cells. AC were used at a 2:1 (AC:cells) concentration for the in vitro 
studies. 
 
Protein extraction 
Protein from joints was harvested as previously described [100], and tissues 
were harvested and snap-frozen in liquid nitrogen. The frozen samples were 
wrapped in aluminum foil and pulverized with a hammer, then placed into 1 ml of 
cold homogenization buffer, HBSS containing 0.2% protease inhibitor cocktail 
(Sigma). Samples were homogenized for 2 minutes on a bead beater and then 
sonicated on ice for 20 seconds at 60% amplitude. Centrifugation (2000 x g for 
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20 minutes, 4°C) and filtration through a 0.45-µm filter were then performed. 
Protein quantity was then assessed via a BCA protein quantification assay 
(Thermo Scientific). Samples were stored at -20°C until used for analysis.  
 
Western blot 
Total protein was isolated as described above, and sample proteins (25 µg) were 
separated on a 10% SDS-PAGE gel and transferred electrophoretically to a 
Trans-Blot nitrocellulose membrane (Bio-Rad). Membranes were blocked with 
5% milk in TBST, then incubated with a 1:1000 dilution of anti-mouse PPAR-γ E8 
(Santa Cruz Biotechnology) or 1:1000 β-actin C4 (Santa Cruz Biotechnology) 
antibody (Ab). Secondary Ab was used as a 1:2000 dilution of goat α-mouse 
(Santa Cruz Biotechnology). The blot was developed using a Pierce ECL 
Western Blotting Substrate (Thermo Scientific) and imaged via x-ray film. 
Densitometry on bands was performed using ImageJ software.  
 
Neutrophil migration assay 
Neutrophil migration assays were performed as previously described [111]. BMN 
were harvested as described above and were incubated with AC at a 2:1 
concentration for 2 hours. Fifty nanograms per milliliter of leukotriene B4 (LTB4; 
Cayman Chemical) was added to the bottom of a 24-well Trans-well plate with a 
3.0-µm polyester membrane (Greiner). Neutrophils were added to the top of the 
Trans-well and allowed to migrate for 2 hours. Cells were then collected from the 
bottom of the well, and the number of neutrophils migrating through the 
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membrane was determined by flow cytometry staining for CD45.2 (eBioscience) 
and Ly6G (BD Biosciences).  
 
Phagocytosis assays 
Neutrophil and macrophage phagocytosis of B. burgdorferi was determined by 
isolating bone marrow-derived macrophages (BMDM) and BMN as previously 
described and preincubating with AC at a 2:1 concentration for 1 hour prior to the 
addition of GFP-expressing B. burgdorferi for the indicated times at a MOI of 10. 
Cells were washed and stained for CD45.2 (eBioscience), F4/80 (eBioscience) 
for macrophages, and Ly6G (BD Biosciences) for neutrophils for flow cytometry 
analysis. The percentage of cells phagocytosing B. burgdorferi was determined 
by the number of GFP+ cells over the total number of cells, expressed as a 
percentage. 
 
RNA isolation for real-time PCR  
RNA was isolated from cells using the RNeasy Mini Kit (Qiagen) according to the 
manufacturer’s protocol. RNA was synthesized into cDNA using the SuperScript 
III First-Strand Synthesis system for RT-PCR (Invitrogen) according to the 
manufacturer’s instructions. Sample cDNA was then diluted to 50 ng/µl and real-
time PCR performed using SYBR Green (Life Technologies). PPAR-γ and CD36 
cycle threshold (CT) values were normalized to GAPDH CT values, with ΔΔCT 
values shown as fold change compared with unstimulated cells. 
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Cell isolation for flow cytometry and apoptotic cell staining 
Inflammatory cells were isolated from ankle joints as previously described [112]. 
Ankles were removed and placed in 15-ml conical tubes containing 5 ml of 1X 
PBS with 4% FBS, 0.03 mg of DNase I (Sigma), and 30 µl of 100 mg/ml stock 
collagenase/dispase (Roche). Samples were placed on a rocker for 1 hour at RT. 
Samples were then placed into sterile petri dishes with RPMI 1640 containing 
10% FBS and flayed apart using sterile forceps. Cells were strained through a 
70-µm filter (Greiner) and washed three times. Live cells were determined by 
counting using trypan blue exclusion. A total of 1 X 106 cells were stained in a 96-
well U-bottom plate (Greiner), with all samples treated with Fc Block (anti-
CD16/CD32; eBioscience), and stained for CD45.2 PE (eBiosciences), F4/80 
APC (eBioscience) and Ly6G PE-Cy7 (BD Biosciences). Cells were washed and 
fixed in 4% paraformaldehyde for 15 minutes. For intra-cellular stains, cells were 
permeabilized with saponin prior to staining with cleaved caspase-3 Alexa Fluor 
488 (Cell Signaling Technology). Joint cellular infiltrate was analyzed using a 
Dako CyAn Flow Cytometer and Summit V5.0 software. 
 
Determination of neutrophil apoptosis 
BMN were harvested as described above and left for indicated times at 37°C in 
5% CO2. Apoptotic neutrophils were determined via flow cytometry by cleaved 
caspase-3+ neutrophils. 
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Macrophage efferocytosis assay 
BMN were harvested as described and labeled with CellTrace Far Red Cell 
Proliferation Kit (APC) (Thermo Fisher), used according to the manufacturer’s 
instructions, and left for 24 hours at 37°C in 5% CO2. Apoptotic neutrophils were 
verified via flow cytometry by cleaved caspase-3+ cells. Apoptotic BMN were 
given to BMDM at a 2:1 concentration and spun at 300 x g for 5 minutes at 4°C. 
After 4 hours, cells were washed and stained for CD45.2 PE (eBioscience) and 
F4/80 APC-Cy7 (eBioscience) for flow cytometry analysis. The percentage of 
macrophages efferocytosing an apoptotic neutrophil was determined by the 
number of APC+ macrophages over the total number of macrophages, expressed 
as a percentage. 
 
Quantification of cytokines by ELISA 
Cytokine levels were measured from cell supernatants or ankle joint 
homogenates [100] using TNF-α (applied Biosystems), IL-10 (BD Biosciences), 
and KC (R&D Biosystems) ELISA kits. Results were reported in picograms per 
milliliter or picograms per milligram protein. 
 
Quantification of cytokines by Luminex 
A Luminex assay (R&D Biosystems) was used to measure apoptotic neutrophil 
production of KC, TNF-α, and IL-10 per manufacturer’s instructions. 
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PPAR-γ agonist and antagonist administration 
The PPAR-γ agonist, rosiglitazone, and antagonist, GW 9662 (Cayman 
Chemical) were used at a 10µM concentration for all in vitro experiments. For in 
vivo experiments, stock rosiglitazone was diluted in sterile PBS to 1mg/ml, and 
10 µl was injected into the tibio-tarsal joint synovial cavities of each mouse on 11 
and 18 days post-infection. 
 
Resolvin E1 administration 
Resolvin E1 (Cayman Chemical) was used at 10nM for all in vitro experiments 
and given 1 hour prior to the addition of GFP B. burgdorferi during the neutrophil 
phagocytosis assay. During macrophage efferocytosis, apoptotic neutrophils 
were cultured in 10nM Resolvin E1, and BMDM were given 10nM Resolvin E1, 3 
hours prior to the addition of the apoptotic neutrophils. 
 
Apoptosis PCR array 
RNA was isolated from cells and synthesized into cDNA as stated above. cDNA 
was used in the RT2 Profiler PCR Array for Apoptosis genes (Qiagen) according 
to the manufacturer’s instructions. Gene expression values are expressed as fold 
change compared to WT apoptotic neutrophils. 
 
FasL and CD36 expression by flow cytometry 
In vitro, BMN were harvested as described above, and left for 24 hours at 37°C in 
5% CO2. In vivo, mice were infected as stated above, and joints were harvested 
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and processed as described above on indicated days post-infection. Cells were 
stained in a 96-well U bottom plate (Greiner) with all samples treated with Fc 
Block (anti-CD16/CD32) (eBioscience) for 15 minutes at 4°C. Cells were then 
stained with the following antibodies: Ly6G PE-Cy7 (BD Biosciences), 
CD178/FasL PE (Biolegend) and CD36 Alexa 488 (Biolegend). MFI of both FasL 
and CD36 was measured on CD45.2+, Ly6G+ cells. 
 
cAMP ELISA 
WT and BLT1-/- BMN were harvested as described and left for 24 hours at 37°C 
in 5% CO2. cAMP Complete ELISA kit (Enzo) was used to measure intracellular 
cAMP according to the manufacturer’s instructions. 
 
Activated apoptotic neutrophils 
Neutrophils were harvested as stated above and given B. burgdorferi or 
Escherichia coli at a MOI of 10. The cells were left for 24 hours at 37°C in 5% 
CO2 in a 96-well U bottom plate (Greiner). Activated apoptotic neutrophils were 
given to BMDM at a 2:1 concentration along with B. burgdorferi at a MOI of 10.  
 
Statistical analysis 
In vivo experiments have groups of n=4 and were performed in duplicate or 
triplicate, and in vitro experiments were performed in duplicate or triplicate with 
n=3. Statistical significance for comparing multiple groups with a single control 
was assessed by ANOVA followed by a Dunnett test, whereas significance 
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among multiple groups was assessed by ANOVA followed by a Bonferroni post-
test. Additional data consisting of two groups used an unpaired, two-tailed, 
Student t test. Statistical significance of differences in histology scores was 
determined by a Mann-Whitney U test. Significance levels are set at p<0.05. 
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Chapter 3 
Treatment of Borrelia burgdorferi-Infected Mice with Apoptotic Cells 
Attenuates Lyme Arthritis via PPAR-γ 
 
Introduction 
Murine Lyme arthritis develops as the result of the infiltration of innate immune 
cells, primarily neutrophils and macrophages. These phagocytic cells are efficient 
in their uptake and killing of B. burgdorferi both in vitro and in vivo [113, 114]. 
Development of arthritis correlates with KC/CXCR2-mediated recruitment of 
neutrophils to the infection joint, followed by inflammatory monocytes [100]. 
While much is known about arthritis induction, little is known about how 
inflammation resolution occurs. Neutrophils are short-lived inflammatory cells 
programmed to undergo apoptosis to limit their pro-inflammatory response. The 
clearance of apoptotic neutrophils by macrophages, efferocytosis, switches them 
from a pro- to an anti-inflammatory state. Additionally, apoptotic cells (AC) have 
been shown to exhibit anti-inflammatory properties and aid in the induction of 
resolution in other models of inflammation [5, 77]. Quantification of AC in the 
joints of B. burgdorferi-infected mice has not been reported, however, the 
clearance of these cells is likely to play an important role in mediating arthritis 
resolution and aid in returning the tissue to homeostasis. 
 
The mechanism by which AC elicit an anti-inflammatory effect is still being 
determined, however, PPAR-γ may be involved. PPAR-γ is a nuclear receptor 
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that mediates transcriptional activation and suppression and is expressed in a 
variety of immune cells, including neutrophils and macrophages [115]. It has 
been shown to suppress inflammatory gene expression in macrophages and 
chemotaxis in neutrophils among other factors [116, 117]. PPAR-γ activation has 
been shown to increase after AC administration in a lung fibrosis model, 
contributing to the down-regulation of pro-inflammatory cytokines, promoting 
inflammation resolution and decreased disease severity [5]. Thus, this study will 
focus on the impact of exogenous administration of AC to promote earlier 
inflammation resolution in B. burgdorferi-infected mice and examine the role of 
AC-mediated PPAR-γ activation during Lyme arthritis resolution. 
 
Results 
Apoptotic neutrophil and macrophage populations mimic changes in ankle 
joint inflammation during Lyme arthritis 
To determine if the number of AC within the infected joint changes over the 
course of infection, ankle joints of C3H B. burgdorferi-infected mice were 
processed for flow cytometry and stained for apoptotic neutrophils and 
macrophages. The number and percentage of apoptotic neutrophils within the 
infected ankle joints significantly increased over the course of infection (Figure 
3A, 3C), as did the number and percentage of apoptotic macrophages (Figure 
3B, 3D). Both apoptotic neutrophils and macrophages increased significantly 
around day 21 post-infection (pi) and peaked at day 28. This correlated well with 
the peak of inflammation, which usually occurs around day 21 in this model. By 
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C3H mice were infected with 1x105 B. burgdorferi and sacrificed at indicated 
days for flow cytometry analysis of joint inflammatory cells. Total cleaved-
caspase-3+ neutrophils (A) and macrophages (B) and percentages of cleaved-
caspase-3+ neutrophils (C) and macrophages (D) of total CD45.2+ inflammatory 
cells were evaluated on 14, 21, 28, 35, and 42 days pi. n = 4 per group. Bars with 
different letters are significantly different from others at the p<0.05 level. 
  
Figure 3: Quantification of apoptotic neutrophils and macrophages within 
B. burgdorferi-infected ankle joints. 
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day 35, most of the AC had been cleared, which correlates well with arthritis 
resolution. 
 
Apoptotic cell treatment limits Lyme arthritis severity and promotes 
resolution but does not impact host response 
Ankle swelling is a convenient way to monitor inflammatory changes within the B. 
burgdorferi-infected joint [99]. To determine if AC administration would alter Lyme 
arthritis progression, AC, (apoptotic Jurkat cells), were administered via intra-
articular ankle injection on 11 and 18 days pi. These timepoints were chosen to 
avoid downregulation of neutrophil and macrophage effector functions during 
times of B. burgdorferi clearance within the ankle joints [3] and to be given earlier 
than when the increase of apoptotic neutrophils and macrophages occurs during 
resolution (Figure 3). Ankle swelling, B. burgdorferi loads within the ankle, and 
inflammatory infiltrates and cytokines within the ankle joints were assessed at 
various time points throughout the infection. As shown in Figure 4, AC or live 
Jurkat cell administration had little or no effect on ankle swelling in uninfected 
mice (Figure 4A), whereas the administration of AC to B. burgdorferi-infected 
mice significantly reduced ankle swelling at 21, 28, and 35 days pi compared with 
infected controls (Figure 4B). The addition of live Jurkat cells had no impact on 
ankle swelling in infected mice throughout the infection (Figure 4B). Similarly, the 
addition of exogenous AC did not impact the host immune response to B. 
burgdorferi infection, as clearance of B. burgdorferi from tissue within the ankle 
joints throughout infection was not altered (Figure 4C). However, analysis of the  
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Figure 4: AC treatment of B. burgdorferi-infected C3H mice. 
C3H mice were uninfected or infected with 1x105 B. burgdorferi and given 
apoptotic Jurkat cells (AC), live Jurkat cells (live JK) or RPMI 1640 control on 
days 11 and 18 pi. Ankle swelling was monitored throughout the experimental 
time course in uninfected (A) or infected (B) mice. Quantification of B. burgdorferi 
loads in the ankle joints was assessed at indicated days pi (C). Infiltrating 
neutrophils and macrophages were quantified on 12 (D) and 19 (E) days pi by 
flow cytometry. Levels of KC (F) and IL-10 (G) were quantified from joint tissue 
on days 12 and 19 pi. n = 4 per group. Asterisk (*) symbols indicate differences 
from infected controls animals at the same time point. *p<0.05, **p<0.01, and 
***p<0.001.  
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joint inflammatory infiltrate on days 12 and 19 pi showed a significant decrease in 
neutrophils within the joints of AC-treated mice compared with control-treated 
animals, whereas macrophage number remained unchanged (Figure 4D, 4E), 
suggesting the presence of the increased number of AC within the joint can limit 
inflammatory processes by decreased neutrophil recruitment and promote earlier 
resolution.  
 
To gain more insight into the mechanism, we attempted to measure cytokine 
production within the infected joint [100]. While the joints expressed no 
detectable levels of TNF-α, similar to a previous report from our lab [100], even 
though TNF-α is typically produced by activated macrophages and is reduced in 
the presence of AC [118]. We have similarly shown that the production of KC is 
critical for neutrophil recruitment and the development of Lyme arthritis [2, 119]. 
However, we did not find an effect of AC treatment on KC levels in the joint 
(Figure 4F). Efferocytosis is known to increase macrophage production of IL-10 
and promote inflammation resolution [120]. We found a trend toward higher IL-10 
levels in the joints of AC-treated mice, but these were not statistically significant 
(Figure 4G). Altogether, these data show that treatment of B. burgdorferi-infected 
mice with AC attenuated Lyme arthritis development and promoted disease 
resolution without a detrimental effect on host response. 
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Apoptotic cells alter macrophage and neutrophil responses in vitro 
We next wanted to determine the effect of AC clearance on unactivated bone 
marrow-derived macrophages (BMDM) or those activated by co-culture with live 
B. burgdorferi. Unactivated BMDM made no detectable levels of TNF-α, or KC 
and only low levels of IL-10, and these were not influenced by the addition of AC 
to the culture (Figure 5A-C). BMDM activated by co-culture with B. burgdorferi, 
however, made high levels of TNF-α and KC and moderate levels of IL-10. The 
addition of AC to these cultures significantly decreased TNF-α and KC levels and 
increased IL-10 levels (Figure 5A-C). Nearly identical results were seen when 
apoptotic neutrophils were used rather than apoptotic Jurkat cells (Figure 6A-C), 
similar to a previous report using bleomycin-activated cells [5]. Therefore, even 
when B. burgdorferi are present, the uptake of AC can significantly decrease 
macrophage inflammatory responses.  
 
We next wanted to determine how AC impacted macrophage and neutrophil 
function, including phagocytosis of B. burgdorferi and chemotaxis. As shown in 
Figure 7A, the presence of AC decreased the percentage of macrophages 
phagocytosing B. burgdorferi. This was true for neutrophils as well (Figure 7B), 
with a significant decrease in the percentage of neutrophils phagocytosing B. 
burgdorferi compared with controls. Live Jurkat cells had no effect on 
macrophage or neutrophil phagocytosis of B. burgdorferi (Figure 7A, 7B). 
Additionally, we wanted to see if AC would impact neutrophil migration to the 
neutrophil chemoattractant Leukotriene B4 (LTB4), known to play an important  
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Figure 5: In vitro quantification of cytokines in C3H BMDM supernatant co-
cultured with AC. 
C3H BMDM were co-cultured with apoptotic Jurkat cells and B. burgdorferi for 24 
hours, and cytokine levels of TNF-α (A), KC (B), and IL-10 (C) were quantified by 
ELISA. n=3 per group. Bars with different letters are significantly different from 
each other at the p<0.05 level.  
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Figure 6: In vitro quantification of cytokines in supernatant of C3H BMDM 
co-cultured with apoptotic neutrophils. 
C3H BMDM were co-cultured with apoptotic neutrophils (AC) and B. burgdorferi 
(Bb) for 24 hours and cytokine levels of TNF-α (A), KC (B), and IL-10 (C) were 
quantified by ELISA. n=3 per group. Bars with different letters are significantly 
different from each other at p<0.05 level. 
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Figure 7: In vitro AC modulation of bacterial clearance and neutrophil 
migration to LTB4. 
C3H BMDM (A) or BMN (B) were co-cultured with AC for 1 hour prior to the 
addition of GFP B. burgdorferi. After 4 hours (A) or 2 hours (B), flow cytometry 
was used to determine the number of GFP+ cells. C3H BMN were co-cultured 
with AC for 2 hours prior to the migration to LTB4 for an additional 2 hours (C). 
n=3 per group. Bars with different letters are significantly different from each 
other at the p<0.05 level. 
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role in neutrophil recruitment during Lyme arthritis [3]. Neutrophil incubation with 
AC significantly decreased the number of neutrophils migrating to LTB4 
compared with controls (Figure 7C). These data show that AC can also alter 
macrophage and neutrophil functions in vitro in the presence of B. burgdorferi. 
 
Apoptotic cells increase PPAR-γ in vitro and in vivo during B. burgdorferi 
infection 
The nuclear transcription factor PPAR-γ is a known negative regulator of 
macrophage activation and plays an important role in AC-mediated anti-
inflammatory processes [5, 116]. We therefore wanted to determine if PPAR-γ 
was being upregulated by AC in our model. We first measured PPAR-γ mRNA 
levels in BMDM cultures alone or in the presence of AC (Figure 8A). Addition of 
AC alone had no effect on macrophage PPAR-γ transcription levels. Activation of 
BMDM by co-culture with B. burgdorferi alone increased PPAR-γ mRNA levels 
by 2-fold, but this was not statistically significant compared with BMDM alone. 
Addition of both B. burgdorferi and AC, however, significantly increased 
macrophage PPAR-γ transcription levels in vitro by almost 5-fold (Figure 8A). We 
then determined if PPAR-γ expression within the ankle joint increased in vivo 
during B. burgdorferi infection following the administration of AC. Administration 
of AC directly into the tibio-tarsal joint at 13 days pi significantly increased PPAR-
γ levels on 14 days pi as measured by western blot (Figure 8B, 8C). These data 
indicate that PPAR-γ is upregulated when AC are cleared during B. burgdorferi  
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Figure 8: AC induction of PPAR-γ in BMDM and C3H infected mouse joints. 
C3H BMDM were co-cultured with AC and/or B. burgdorferi for 24 hours, and 
PPAR-γ transcription was determined by real-time PCR (A). n=3 per group. C3H 
mice were infected with 1x105 B. burgdorferi and given apoptotic Jurkat cells or 
RPMI 1640 (mock) on day 13 pi. Mice were sacrificed 24 hours later, and PPAR-
γ expression in the ankle joints was determined via western blot (B) and 
densitometry (C). n=4 per group. Bars with different letters are significantly 
different from each other at the p<0.05 level.  
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infection and could possibly explain how AC contribute to inflammation 
resolution.  
 
The PPAR-γ agonist rosiglitazone alters macrophage cytokine production 
and neutrophil migration in vitro 
To further confirm the role of PPAR-γ in AC alteration of immune cells, we next 
determined if using the PPAR-γ agonist rosiglitazone would cause a similar 
alteration in cytokine production of B. burgdorferi co-cultured macrophages as 
AC. B. burgdorferi co-cultured macrophages treated with rosiglitazone had 
significantly reduced levels of TNF-α (Figure 9A) and KC (Figure 9B) and 
significantly increased levels of IL-10 (Figure 9C), which were similar to trends 
shown with AC (Figure 5 & 6). In contrast, treatment of BMDM with the PPAR-γ 
inhibitor GW 9662 partially but significantly counteracted the effect of AC on 
macrophage TNF-α and KC production (Figure 9D, 9E) and completely inhibited 
the AC induction of IL-10 (Figure 9F).  
 
We next investigated the effect of PPAR-γ on neutrophil migration and 
macrophage and neutrophil phagocytosis of B. burgdorferi. In contrast to the 
inhibitory effects of AC on macrophage and neutrophil phagocytosis of B. 
burgdorferi, treatment of BMDM and bone marrow neutrophils (BMN) with 
rosiglitazone or GW9662 had no effect on their ability to phagocytose B. 
burgdorferi (Figure 10A, 10B, 10E, 10F). These data suggest that AC induce 
other signals besides PPAR-γ activation, which impacts bacterial phagocytosis.  
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Figure 9: Effect of PPAR-γ modulation on BMDM cytokine production. 
C3H BMDM were co-cultured with the PPAR-γ agonist rosiglitazone (RSG) 
and/or B. burgdorferi (A-C) or B. burgdorferi and AC and/or the PPAR-γ 
antagonist GW 9662 (D-F) for 24 hours, and levels of TNF-α (A and D), KC (B 
and E), and IL-10 (C and F) were quantified by ELISA. n=3 per group. Bars with 
different letters are significantly different from each other at the p<0.05 level. 
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Figure 10: Effect of PPAR-γ modulation of bacterial clearance, neutrophil 
migration to LTB4, and efferocytosis. 
C3H BMDM (A and E) or BMN (B and F) were given rosiglitazone (RSG) or GW 
9662 and/or AC for 2 hours (BMN) or 4 hours (BMDM) prior to the addition of 
GFP B. burgdorferi for 4 hours. Flow cytometry was used to determine the 
number of GFP+ cells. n=3 per group. C3H BMN were given RSG (C) or GW 
9662 and or AC (G) for 2 hours prior to migration to LTB4 for an additional 2 
hours. C3H BMDM were treated with RSG (D) or GW 9662 (H) for 1 hour prior to 
the addition of CFSE-labeled AC. The percentage of cells containing AC was 
determined after 4 hours by flow cytometry. n=3 per group. Bars with different 
letters are significantly different from each other at the p<0.05 level.  
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Similar to the effect of AC, treatment of neutrophils with rosiglitazone inhibited 
their migration toward LTB4 (Figure 10C), and treatment with GW 9662 
modulated the effects of AC on neutrophil migration (Figure 10G), suggesting 
neutrophil recruitment is primarily impacted by PPAR-γ mediated mechanisms. 
Finally, PPAR-γ activation appears to have little effect on efferocytosis, treatment 
of BMDM with either rosiglitazone or GW 9662 did not alter macrophage 
clearance of AC in vitro (Figure 10D, 10H).  
 
Rosiglitazone treatment reduces ankle swelling during Lyme arthritis and 
suppresses inflammatory cell recruitment 
Finally, we wanted to determine if administration of rosiglitazone in vivo during B. 
burgdorferi infection would impact ankle swelling and immune cell recruitment to 
the ankle joints. By administering rosiglitazone directly into the ankle joint, as we 
previously did with AC, ankle swelling was significantly reduced at 21 days pi 
compared to controls (Figure 11A), similar to treatments with AC. Additionally, 
both neutrophil (Figure 11B, 11E) and macrophage (Figure 11C, 11F) numbers 
were significantly reduced in the rosiglitazone-treated mice on both 28 and 35 
days pi. These data show that rosiglitazone treatment decreases ankle swelling 
and inflammatory cell recruitment to the ankle joints during B. burgdorferi 
infection. Unexpectedly, rosiglitazone treatment decreased B. burgdorferi loads 
in the ankle joints on day 28 pi and significantly lowered spirochete loads on day 
35 pi (Figure 11D). This effect was not seen during AC treatment of B.  
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Figure 11: Rosiglitazone treatment of B. burgdorferi-infected C3H mice. 
C3H mice were infected with 1x105 B. burgdorferi and given rosiglitazone or 
DMSO on days 11 and 18 pi. Ankle swelling was monitored throughout the 
infection time course (A). Numbers of neutrophils (B and E) and macrophages (C 
and F) within the ankle joints were evaluated on days 28 and 35 pi. B. burgdorferi 
levels in ankle joints were determined by real-time PCR (D). n=4 per group. An 
asterisk (*) indicates statistical difference from DMSO control at the same time 
point at the p<0.05 level. Bars with different letters are significantly different from 
each other at p<0.05 level. *=p<0.05. 
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burgdorferi-infected mice (Figure 4C) and suggests that rosiglitazone may induce 
bacterial clearance by other mechanisms besides PPAR-γ activation [121]. 
 
Discussion 
The recruitment of neutrophils is known to drive the development of murine Lyme 
arthritis, however, the mechanisms of how disease resolution occurs remains 
unclear. The efficient clearance of AC likely plays a role during arthritis 
resolution; however, this has never been proven in vivo. The purpose of this 
study was to determine the role of AC during inflammation resolution in B. 
burgdorferi-infected mice and define a mechanism of how this occurs. As shown 
with the use of flow cytometry, the number of apoptotic neutrophils and 
macrophages, the main inflammatory infiltrates, increased within the ankle joints 
of B. burgdorferi-infected mice, peaking during inflammation resolution, around 
28 days post infection. Additionally, the injection of AC directly into the ankles of 
B. burgdorferi-infected mice limited ankle swelling and decreased neutrophil 
recruitment to the joints without interfering with bacterial clearance. This is a 
similar phenomenon seen in other models of inflammation [5, 77], and further 
shows the therapeutic potential of apoptotic cells. 
 
 In vitro, the addition of AC to BMDM cultures decreased B. burgdorferi-induced 
TNF-α and KC and increased IL-10. In addition, phagocytosis of B. burgdorferi 
and neutrophil migration to LTB4 were inhibited by AC, showing that AC can 
modulate the pro-inflammatory nature of macrophages and neutrophils into an 
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anti-inflammatory state. The administration of exogenous AC increased PPAR-γ 
expression both in vitro and in vivo during B. burgdorferi infection, showcasing a 
possible mechanism to explain the involvement of AC in inflammation resolution. 
The PPAR-γ agonist, rosiglitazone, elicited similar changes in macrophage 
cytokine production and neutrophil migration as the use of exogenous AC. The 
addition of the PPAR-γ antagonist GW 9662 abrogated the effects of AC in vitro, 
further demonstrating the probable role of PPAR-γ in this system. Injection of 
rosiglitazone directly into the tibio-tarsal joints of B. burgdorferi-infected mice 
decreased ankle swelling and immune cell recruitment, similar to the injection of 
AC, further explaining how AC are able to elicit their anti-inflammatory response 
during B. burgdorferi infection. These results suggest clearance of AC plays a 
role in the resolution of inflammation during experimental Lyme arthritis through 
the activation of PPAR-γ. Therefore, PPAR-γ agonists, such as rosiglitazone, may 
be useful to ameliorate Lyme arthritis and induce resolution in individuals with 
posttreatment Lyme disease syndrome. This would be an improvement from 
current therapeutic strategies that treat the symptoms of the disease, rather than 
inducing inflammation resolution. 
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Chapter 4 
Leukotriene B4 Signaling Through BLT1 Promotes Efferocytosis and 
Inflammation Resolution During Lyme Arthritis 
 
Introduction 
The clearance of apoptotic immune cells by macrophages, efferocytosis, is now 
considered a critical component driving the resolution of inflammation [43]. 
Neutrophils recruited to the site of infection or injury are programmed to undergo 
apoptosis to limit their pro-inflammatory responses [122]. The uptake and 
clearance of apoptotic cells has a profound effect on macrophages, including to 
down-regulate pro-inflammatory cytokine production and increase their 
production of anti-inflammatory mediators, such as IL-10 and PGE2 [118]. 
However, failure to clear apoptotic cells in a timely manner may result in the 
apoptotic cells undergoing a secondary necrosis and prolonging inflammatory 
responses [123]. Therefore, a breakdown in apoptosis or efferocytosis can 
increase inflammation, rather than down-regulate it. 
 
Previous work in our lab has shown in B. burgdorferi-infected mice, 5-
lipoxygenase (5-LO)-/- mice experienced exacerbated and prolonged arthritis [3]. 
This was despite normal anti-Borrelia antibody production and spirochete 
clearance from joint tissues. In contrast, mice deficient in 5-LO activating protein 
were protected from arthritis development in the collagen-induced arthritis (CIA) 
model of rheumatoid arthritis [124]. During inflammatory processes, arachidonic 
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acid (AA) is released from the membrane by cytosolic phospholipase A2 (cPLA2). 
AA can then be metabolized by 5-LO into the pro-inflammatory lipids, leukotriene 
(LT)B4 or the cysteinyl LT [125]. However, 5-LO also produces anti-inflammatory 
lipids, such as AA derived lipoxins and omega-3 fatty acid derived specialized 
pro-resolving mediators (SPM), such as D-series resolvins from 
docosahexaenoic acid (DHA) and E-series from eicosapentaenoic acid (EPA) 
[126]. The production of lipoxins has been correlated with the resolution of 
arthritis in the CIA model [127], and the therapeutic treatment of mice with a 
lipoxin receptor agonist was also able to reduce severity in established CIA [128]. 
Similarly, treatment of mice with Resolvin D1 or E3 attenuated arthritis severity in 
the K/BxN serum-transfer model [129, 130]. These results showcase the complex 
nature of bioactive lipid regulation of inflammatory responses and demonstrate 
that 5-LO metabolites have both pro-inflammatory and pro-resolution effects on 
inflammation. 
 
Previous work demonstrated a defect in efferocytosis by 5-LO-deficient 
macrophages which correlated with nonresolution during Lyme arthritis [3]. In this 
study, we focus on the role of the 5-LO metabolite, LTB4, on Lyme arthritis 
development and resolution through the use of BLT1-/- mice. While LTB4 has two 
receptors, BLT1 being the high affinity and BLT2 being the low affinity, the focus  
of this study will be on BLT1, because it is only located on leukocyte subsets 
while BLT2 is more constitutively expressed [131]. This approach has the 
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advantage of leaving other 5-LO-mediated pathways intact, especially those 
important for inflammation resolution [132]. 
 
Results 
Assessment of B. burgdorferi infection of BLT1-/- mice 
We have previously reported that infection of mice deficient in 5-LO with B. 
burgdorferi led to exacerbated development of experimental Lyme arthritis and a 
deficiency of arthritis resolution and prolonged disease [3]. Since 5-LO is 
responsible for the production of several pro- and anti-inflammatory mediators, 
we decided to first focus on the role of LTB4 in mediating this response since we 
have previously shown its expression in the ankle joints during B. burgdorferi 
infection [3]. C3H WT and C3H BLT1-/- mice were infected with 1x105 B. 
burgdorferi and development of arthritis was followed by monitoring ankle 
swelling on a weekly basis. During the early part of infection, BLT1-/- mice 
developed ankle swelling similar to WT mice (Figure 12A) However, at later time 
points, resolution of joint swelling in the BLT1-/- mice appeared to lag behind the 
WT mice, and at day 35 pi was significantly higher before returning to baseline 
levels on day 42 pi. Lack of BLT1 signaling had no effect on spirochete clearance 
from joint tissues indicating host defense remained intact (Figure 12B). However, 
ankle swelling is not always indicative of the underlying inflammatory response. 
Assessment of H&E stained sections from infected joints on day 14 pi revealed 
relatively equal levels of inflammatory infiltrates at this time point (Figure 12C). 
However, by day 35 pi, a time when WT were undergoing arthritis resolution,  
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Figure 12: Ankle swelling, B. burgdorferi loads and arthritis severity in B. 
burgdorferi-infected C3H WT and BLT-/- mice. 
C3H WT and BLT1-/- mice were infected with 1x105 B. burgdorferi. (A) Ankle 
swelling was monitored weekly throughout infection. (B) Quantification of B. 
burgdorferi loads of the ankle joints were assessed at indicated days post-
infection. (C) Arthritis scores were determined by histological analysis of the 
ankle joints via H&E staining on days 14 and 35 post-infection. (D) 
Representative H&E stained joint sections on day 35 post-infection. Magnification 
40x. n=4 per group. * indicates significance at P<0.05 level.  
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ankle joints from BLT1-/- mice exhibited severe inflammation and high arthritis 
severity scores. This is exemplified by representative images of inflammation 
around the cranial tendon in the joint, which is mild in the WT mice and quite 
severe in the BLT1-/- mice (Figure 12D). These results demonstrate the lack of 
LTB4 signaling through BLT1 has little effect on the development of experimental 
Lyme arthritis, but results in a lack of normal arthritis resolution and chronic 
inflammation. 
 
Assessment of joint cellular infiltrate in WT and BLT1-/- mice during B. 
burgdorferi infection 
Infection of BLT1-/- mice with B. burgdorferi resulted in the normal development of 
Lyme arthritis with a failure to undergo normal arthritis resolution and an 
exacerbation of disease severity and duration. We next used flow cytometry to 
compare joint cellular infiltrates between WT and BLT1-/- mice. Mice were 
infected as before, and joints were harvested on days 14, 28, and 35 pi and 
cellular infiltrates isolated for flow analysis. On day 14 pi, a time point when 
arthritis severity scores were similar between WT and BLT1-/- mice, total 
neutrophil numbers in the joints were similar although there was a trend for 
higher numbers in the BLT1-/- mice (Figure 13A). However, by day 28 pi, a time 
point when arthritis resolution is beginning to occur in WT mice, BLT1-/- have 
significantly higher total neutrophil numbers in their joints compared to WT joints 
(Figure 13B). This difference was even greater by day 35 pi (Figure 13C). 
Similarly, the  
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Figure 13: Quantification of neutrophils within the ankle joints of B. 
burgdorferi-infected WT and BLT1-/- mice. 
C3H WT and BLT1-/- mice were infected with 1x105 B. burgdorferi and sacrificed 
at indicated days for flow cytometry analysis. Total number of neutrophils (A-C) 
and the percentage of cleaved-caspase 3+ neutrophils (D-F) were evaluated on 
days 14, 28, and 35 post-infection. n=4 per group. Bars with different letters are 
significantly different from others a P<0.05 level.  
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percentage of neutrophils undergoing apoptosis, as measured by cleaved-
caspase 3 [133], was similar at day 14 pi, but significantly lower in the BLT1-/- 
joints on days 28 and 35 (Figure 13D-F). This difference appears to be mediated 
primarily by differences in neutrophils, as macrophage numbers remain similar 
until much later during infection (Figure 14A-C). This late increase in 
macrophages may be due to the prolonged presence of neutrophils in the BLT1-/- 
mice. Overall, these data suggest decreased neutrophil apoptosis and clearance 
may be contributing to the defect in inflammation resolution in BLT1-/- mice. 
 
In vitro characterization of BLT1-/- neutrophils 
Neutrophil populations were significantly altered at later time points in B. 
burgdorferi-infected BLT1-/- mice. Therefore, we sought to identify intrinsic 
defects in BLT1-/- neutrophils. We first determined if BLT1-/- neutrophils had a 
defect in their ability to undergo apoptosis. WT and BLT1-/- BMN were isolated 
from bone marrow and left as described for 24 hours, and apoptosis was then 
measured by quantifying cleaved-caspase 3+ cells by flow cytometry. When 
cultured in media alone, BLT1-/- BMN had a significantly lower percentage of 
apoptotic neutrophils compared with WT BMN (Figure 15A). However, when co-
cultured with B. burgdorferi, the percentage of apoptotic neutrophils was similar 
between the two groups, but significantly lower than control cultures. Thus, 
uptake of B. burgdorferi appears to delay apoptosis in both WT and BLT1-/- BMN. 
We next examined the ability of BLT1-/- BMN to phagocytose B. burgdorferi. After  
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Figure 14: Quantification of macrophages within the ankle joints of B. 
burgdorferi-infected WT and BLT1-/- mice. 
C3H WT and BLT1-/- mice were infected with 1x105 B. burgdorferi and sacrificed 
at indicated days for flow cytometry analysis. Total number of macrophages (A-
C) were evaluated on days 14, 28, and 35 post-infection. n=4 per group. Bars 
with different letters are significantly different from others at P<0.05 level. 
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Figure 15: Effector functions of WT and BLT1-/- neutrophils and 
macrophages in vitro. 
(A) C3H WT and BLT1-/- BMN were given B. burgdorferi and stained for cleaved-
caspase 3 after 24 hours for flow cytometry. (B) C3H WT and BLT1-/- BMN were 
given GFP-B. burgdorferi for 2 hours with flow cytometry used to determine the 
number of GFP+ neutrophils. (C) C3H WT and BLT-/- BMN were allowed to 
migrate to LTB4 for 2 hours. Flow cytometry was used to determine the number 
of neutrophils which had migrated through the trans-well. (D) C3H WT and BLT1-
/- BMDM were given labeled WT or BLT1-/- apoptotic BMN for 4 hours. Flow 
cytometry was used to determine the number of BMDM with labeled apoptotic 
neutrophils. n=3 per group. Bars with different letters are significantly different 
from others and P<0.05 level. * indicates significance at P<0.05 level. 
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2 hours of co-culture, BLT1-/- BMN had a significant reduction in B. burgdorferi 
phagocytosis compared to WT BMN (Figure 15B). This is similar to defects in 
phagocytosis of B. burgdorferi previously shown in both BLT1-/- [134] and 5-LO-/- 
[3] macrophages. 
 
An important function of LTB4 is the recruitment of neutrophils, however 
neutrophils seem to be in abundance in B. burgdorferi-infected BLT1-/- mice 
(Figure 13) and in 5-LO-/- mice [3] which are deficient in LTB4. We confirmed that 
BLT1-/- BMN have a significant defect in migration to LTB4 compare to WT BMN 
after 2 hours of migration (Figure 15C). Subbarao et al. have previously reported 
BLT1-/- neutrophils required 100x greater LTB4 to migrate at the same rate as WT 
macrophages [135], therefore other neutrophil chemo-attractants, such as KC, 
are more likely responsible for neutrophil recruitment during B. burgdorferi 
infection [2]. The continued presence of neutrophils in the B. burgdorferi-infected 
joints at late time points in the BLT1-/- mice suggests there may be a defect in 
clearance of these cells. To determine if BLT1-/- macrophages were defective 
during efferocytosis, WT or BLT1-/- BMDM were co-cultured with either WT or 
BLT1-/- labeled apoptotic BMN for 4 hours. As shown in Figure 15D, WT and 
BLT1-/- BMDM were equally efficient at the clearance of WT apoptotic BMN, 
however, both WT and BLT1-/- macrophages had a significant reduction in the 
clearance of BLT1-/- apoptotic BMN. This demonstrates BLT1-/- BMDM are 
competent to clear WT apoptotic BMN, but both WT and BLT1-/- BMDM have a 
defect in the clearance of BLT1-/- apoptotic BMN. Therefore, BLT1-/- apoptotic 
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BMN are defective in mediating their own clearance by macrophages and may 
be responsible for the lack of arthritis resolution in the BLT1-/- mice.  
 
Resolvin E1 restores neutrophil apoptosis and B. burgdorferi phagocytosis 
in BLT1-/- neutrophils, however it does not affect macrophage efferocytosis  
Resolvin E1 is an eicosapentaenoic acid (EPA) derived poly-unsaturated fatty 
acid (PUFA) with two receptors, BLT1 and ChemR23 [136]. Upon binding, 
Resolvin E1 enhances neutrophil apoptosis [137], reduces neutrophil migration 
[138], and enhances bacterial phagocytosis and apoptotic cell efferocytosis [139, 
140]. We wanted to determine if decreased Resolvin E1 signaling was causing 
the alteration in neutrophil functions in BLT1-/- mice. Administration of exogenous 
Resolvin E1 slightly enhanced neutrophil apoptosis in BLT1-/- BMN after 18 hours 
(Figure 16A) and enhanced B. burgdorferi phagocytosis in both WT and BLT1-/- 
neutrophils (Figure 16B). However, Resolvin E1 had no effect on efferocytosis in 
BLT1-/- apoptotic neutrophils (Figure 16C). This data indicates while Resolvin E1 
aids in restoration of BLT1-/- neutrophil apoptosis and B. burgdorferi 
phagocytosis, it does not affect efferocytosis, indicating additional mechanisms 
may be causing the defect in inflammation resolution in BLT1-/- mice, most likely 
responsible for the decreased ability to recognize BLT1-/- apoptotic neutrophils. 
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Figure 16: Effector functions of WT and BLT1-/- neutrophils and 
macrophages in vitro with Resolvin E1. 
(A) WT and BLT1-/- BMN were given Resolvin E1 and stained for cleaved 
caspase-3 after 18 hours for flow cytometry. (B) WT and BLT1-/- BMN were given 
Resolvin E1 1 hour prior to the addition of GFP-B. burgdorferi for 2 additional 
hours. Flow cytometry was used to determine the number of GFP+ neutrophils. 
(C) WT and BLT1-/- BMDM were given Resolvin E1 3 hours prior to the addition of 
labeled WT or BLT1-/- apoptotic BMN, which had been cultured in Resolvin E1, for 
4 hours. Flow cytometry was used to determine the number of BMDM with a 
labeled apoptotic neutrophil. n=3 per group. Bars with different letters are 
significantly different from others at a P<0.05 level. 
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BLT1-/- apoptotic BMN have decreased TNF-α production and DISC 
formation 
While we have shown BLT1-/- apoptotic BMN have a defect in recognition by 
macrophages (Figure 15D), we next determined if BLT1-/- apoptotic BMN had 
altered cytokine production or expression of apoptotic genes compared to WT 
apoptotic BMN. Freshly isolated BMN from WT or BLT1-/- mice were cultured in 
media for 24 hours, and supernatant was harvested. Apoptotic BLT1-/- BMN had 
significantly decreased TNF-α production compared to WT apoptotic BMN 
(Figure 17A), however, quantification of KC (Figure 17B) and IL-10 (Figure 17C) 
showed no difference between BLT1-/- and WT apoptotic BMN.  
 
In addition, we were interested in defining changes in the expression of genes 
associated with apoptosis in BLT1-/- apoptotic BMN. To do this we used the 
apoptosis profiler PCR array which measures the expression of 84 key genes 
involved in apoptosis. WT and BLT1-/- BMN were cultured in media for 24 hours. 
Cells were harvested and mRNA extracted, cDNA made and normalized to 
control. Of the 84 genes tested (Appendix 1) 14 were significantly downregulated 
in expression, indicated by a greater than 2-fold difference in the BLT1-/- 
compared to WT BMN (Table 1). Five of the genes downregulated in BLT1-/- 
apoptotic BMN, including Cradd, Fadd, Fas, Ltbr, and Traf1, are associated with 
the death-inducing signaling complex (DISC) [141-144]. This complex is 
important for TNF-induced apoptosis which is mediated through Fas/FasL 
interaction [141]. Three additional genes downregulated in BLT1-/- apoptotic  
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Figure 17: Cytokine production of WT and BLT1-/- apoptotic neutrophils in 
vitro. 
WT and BLT1-/- BMN were harvested and left for 24 hours. Supernatant was 
harvested, and the cytokines TNF-α (A), KC (B), and IL-10 (C) were measured by 
Luminex Assay. n=3 per group. Bars with different letters are significantly 
different from others at P<0.05 level.  
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Table 1: PCR array of apoptosis associated gene expression in BLT1-/- 
apoptotic neutrophils compared to WT. 
cDNA was harvested from WT and BLT1-/- apoptotic neutrophils and ran on the 
Apoptosis RT2 Profiler PCR Array. The genes shown here had a greater than 2-
fold decrease in expression in the BLT1-/- apoptotic neutrophils compared to WT. 
  
Abl1 C-abl oncogne 1, non-receptor tyrosine kinase -2.42 
Bax Bcl2-assiciated X-protein -2.07 
Bcl2a1a B-cell leukemia/lymphoma 2 related protein A1a -2.16 
Bcl2l1 Bcl2-like 1 -2.52 
Card10 Caspase recruitment domain family, member 10 -2.04 
Casp14 Caspase 14 -2.16 
Casp3 Caspase 3 -2.06 
Cradd CASP2 and RIPK1 domain containing adaptor with death 
domain 
-2.03 
Fadd Fas (TNFRSF6)-assicated via death domain -2.39 
Fas Fas (TNF receptor superfamily member 6) -2.28 
Igf1r Insulin-like growth factor I receptor -2.40 
Ltbr Lymphotoxin B receptor -2.06 
Traf1 Tnf receptor-associated factor1 -2.06 
Trp53 Transformation related protein 53 -2.50 
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neutrophils, Abl1, Bax, and Caspase 3, are downstream of the DISC signaling 
[145, 146]. We next confirmed decreased expression of the DISC components 
and downstream effectors in BLT1-/- apoptotic BMN compared to WT both in vitro 
and in vivo by using flow cytometry (Figure 18). FasL expression was used to 
assess DISC formation, while CD36, important for apoptotic cell recognition and 
efferocytosis, was used to determine downstream effects of DISC formation [141, 
147]. Both FasL (Figure 18C) and CD36 (Figure 18D) expression were 
significantly decreased in BLT1-/- neutrophils compared to WT in vivo at day 14 
pi. Thus, BLT1-/- apoptotic BMN have decreased TNF-α expression and a 
downregulation of the formation of components and downstream effects of the 
DISC, which is responsible for TNF-induced apoptosis.  
 
BLT1-/- apoptotic neutrophils have increased cAMP, preventing DISC 
formation 
We have shown BLT1-/- neutrophils have decreased DISC formation, possibly 
causing a defect in the induction of apoptosis and recognition by phagocytic 
cells. Battacharjee et al. demonstrated cyclic-AMP (cAMP) prevents TNF-
induced apoptosis by inhibiting DISC formation [141]. LTB4 downregulates cAMP 
via BLT1 signaling [148], and our lab has previously shown LTB4 decreases 
cAMP in BMDM [134], therefore we wanted to determine if BLT1-/- apoptotic 
neutrophils were unable to downregulate cAMP, preventing DISC formation. As 
shown in Figure 19, BLT1-/- apoptotic neutrophils had significantly increased 
levels of cAMP compared to WT. This data suggests the inability to downregulate  
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Figure 18: FasL and CD36 expression on WT and BLT1-/- apoptotic 
neutrophils in vitro and B. burgdorferi-infected joint neutrophils on day 14 
pi in vivo. 
WT and BLT1-/- BMN were harvested and left for 24 hours. FasL (A) and CD36 
(B) was measured by mean fluorescence intensity (MFI) by flow cytometry. WT 
and BLT1-/- mice were infected with 1x105 B. burgdorferi and sacrificed at day 14 
pi for flow cytometry analysis. FasL (C) and CD36 (D) MFI was measured on 
CD45.2+, Ly6G+ neutrophils. n=3 per group. Bars with different letters are 
significantly different from others at P<0.05 level. 
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Figure 19: Levels of cAMP in WT and BLT1-/- apoptotic neutrophils. 
WT and BLT1-/- BMN were harvested and left for 24 hours. Intracellular cAMP 
was measured by ELISA. n=3 per group. Bars with different letters are 
significantly different from others at P<0.05 level. 
  
 70 | P a g e  
 
cAMP in BLT1-/- neutrophils prevents DISC formation, therefore causing 
decreased apoptotic cell recognition and a defect in efferocytosis leading to 
prolonged inflammation and a defect in arthritis resolution.  
 
Discussion 
During Lyme arthritis, it is known neutrophil recruitment to the ankle joints drives 
arthritis development, but the mechanisms involved in arthritis resolution remain 
unclear. The clearance of apoptotic cells is important during Lyme arthritis 
resolution, however, if there is a breakdown in apoptosis or efferocytosis, the 
cells can undergo a secondary necrosis and further contribute to the 
inflammatory response. Previously, infection of 5-LO-/- mice with B. burgdorferi 
resulted in normal arthritis development but had failed arthritis resolution and 
decreased macrophage efferocytosis [3]. LTB4 is a pro-inflammatory downstream 
product of 5-LO and signals through BLT1 or BLT2 [131]. BLT1 is the high-affinity 
receptor found mainly on leukocytes [131], therefore we wanted to determine if 
signaling through this receptor was responsible for the failure of arthritis 
resolution in the 5-LO-/- mice. Here we show BLT1-/- mice infected with B. 
burgdorferi developed arthritis similar to WT mice but failed to undergo arthritis 
resolution as with 5-LO-/- mice. This failure was characterized by increased ankle 
swelling and prolonged cellular infiltrate in the joints of BLT1-/- mice compare to 
WT mice. Also similar to 5-LO-/-, these mice had similar bacterial loads of B. 
burgdorferi throughout infection as WT mice. Although there was an increased 
presence of neutrophils in the joints of BLT1-/- during resolution, there was a 
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lower percentage of apoptotic neutrophils suggesting a defect in neutrophil 
apoptosis and clearance. In vitro, BLT1-/- neutrophils had a slight delay in 
apoptosis and a defect B. burgdorferi phagocytosis, along with BLT1-/- apoptotic 
neutrophils causing a significant decrease in efferocytosis in both WT and BLT1-/- 
macrophages. This suggested the defect associated with BLT1-/- may be the 
result of a defect in BLT1-/- apoptotic cells. Additionally, the administration of 
Resolvin E1, a pro-resolving mediator known to signal through BLT1, was able to 
restore apoptosis and B. burgdorferi phagocytosis in BLT1-/- neutrophils, however 
it had no effect on efferocytosis.  
 
As determined by PCR Array and flow cytometry, Death-induced signaling 
complex (DISC) formation was defective in BLT1-/- apoptotic neutrophils, which 
caused decreased CD36 expression, a downstream effector of DISC. 
Additionally, the cause of decreased DISC formation was from BLT1-/- apoptotic 
neutrophils inability to downregulate cAMP through LTB4 signaling. These results 
suggest that in addition to being a primary driver of neutrophil recruitment and 
inflammation, LTB4 signaling through BLT1 is also an important component of 
neutrophils apoptosis. Inhibition of this signaling pathway can lead to prolonged 
inflammation by inhibiting neutrophil apoptosis and clearance and promoting the 
development of chronic inflammatory disease. 
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Chapter 5 
The Effects of Apoptotic Cell Secretions and Activated Apoptotic Cells on 
Innate Immune Cell Function 
 
Introduction 
Apoptosis was first thought of as a passive process and was only involved in 
normal cell turnover, such as recycling of red blood cells and skin cells, however, 
recent studies have found it has a dynamic role in the down-regulation of pro-
inflammatory responses. Phosphatidylserine (PS) on the outside of the cell is one 
of the hallmark characteristics of AC and is involved in its recognition and 
engulfment by phagocytic cells [19]. While recognition of PS is involved in the 
down-regulation of inflammatory responses of macrophages and dendritic cells 
through efferocytosis, AC themselves can also secrete factors that also play a 
role in modulating immune responses to neighboring cells [149]. Several 
cytokines have been previously shown to be secreted by apoptotic cells, 
including IL-10 and IL-38, to modulate immune responses [150]. Additionally, the 
eicosanoid PGE2 is produced by dying cells and acts as an inhibitory danger 
associated molecular pattern (iDAMP) to prevent cell death associated 
inflammation [151]. While we and others have shown the presence of AC alters 
macrophage and neutrophil effector functions [6, 118], we next wanted to 
determine if the secreted products of AC could modulate innate cell function in a 
similar or partial capacity compared to the presence of the entire AC itself.  
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During the immune response to B. burgdorferi infection in mice, neutrophils are 
first recruited to the joints to phagocytose the spirochetes and then undergo 
apoptosis [6]. Macrophages and other phagocytic cells are recruited for 
efferocytosis of apoptotic neutrophils containing phagocytosed B. burgdorferi. 
Therefore, we developed an in vitro system to better replicate in vivo timing of 
bacterial presence, neutrophil recruitment, and effector function modulation of 
immune cells after efferocytosis.  
 
Bacterially-activated apoptotic neutrophils have been reported to have various 
impacts on inflammation and disease. The efferocytosis of apoptotic Escherichia 
coli-infected dendritic cells promoted high levels of anti-inflammatory cytokine 
production, while suppressing inflammatory pathways, causing the down-
regulation of inflammation and promoting resolution [57]. However, Klebsiella 
pneumoniae infection of neutrophils impaired efferocytosis clearance by 
modulation of cell host machinery, causing prolonged survival and inflammation 
[152]. Therefore, neutrophil activation by B. burgdorferi could potentially have 
either positive or negative impact on the immune response and inflammation 
resolution. Thus, this study will focus on how AC secretions and B. burgdorferi-
activated apoptotic neutrophils modulate macrophage and neutrophil functions in 
vitro. 
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Results 
Apoptotic cell supernatant alters macrophage and neutrophil responses in 
vitro 
We first wanted to determine how the administration of supernatant from 
apoptotic Jurkat cells influenced macrophage cytokine production when co-
cultured with B. burgdorferi. Shown in Figure 20, the administration of these AC 
to B. burgdorferi co-cultured macrophages significantly decreased pro-
inflammatory cytokines TNF-α (Figure 20A) and KC (Figure 20B) and increased 
anti-inflammatory IL-10 (Figure 20C), as we have previously shown (Figure 5). 
Additionally, the administration of the AC supernatant caused a similar TNF-α 
decrease as did the apoptotic Jurkat cells (Figure 20A). However, the AC 
supernatant had no effect on KC (Figure 20B) or IL-10 (Figure 20C) production, 
showing the AC supernatant alone could only alter some of the cytokines known 
to be modulated by AC. 
 
We next wanted to determine if the AC supernatant alone could alter 
macrophage and neutrophil B. burgdorferi phagocytosis and neutrophil migration 
in a similar fashion as AC (Figure 7). Both macrophage and neutrophil 
phagocytosis of B. burgdorferi was not affected by the co-culture with live Jurkat 
cells or Jurkat cell supernatant (Figure 21A, 21B), however, the administration of 
both apoptotic Jurkat cells and apoptotic Jurkat cell supernatant significantly 
decreased the percentage of macrophages (Figure 21A) phagocytosing B.  
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Figure 20: In vitro quantification of cytokines in C3H BMDM supernatant co-
cultured with AC and AC supernatant. 
C3H BMDM were co-cultured with either apoptotic Jurkat cells (AC) or apoptotic 
Jurkat cell supernatant (ACS) with B. burgdorferi for 24 hours, and cytokines 
levels of TNF-α (A), KC (B), and IL-10 (C) were quantified by ELISA. n=3 per 
group. Bars with different letters are significantly different from each other at the 
p<0.05 level.  
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Figure 21: In vitro AC and AC supernatant modulation of bacterial 
clearance and neutrophil migration to LTB4. 
C3H BMDM (A) or BMN (B) were co-cultured with AC or ACS for 1 hour prior to 
the addition of GFP B. burgdorferi. After 4 hours (A) or 2 hours (B), flow 
cytometry was used to determine the number of GFP+ cells. C3H BMN were co-
cultured with AC or ACS for 2 hours prior to the migration to LTB4 for an 
additional 2 hours (C). Bars with different letters are significantly different from 
each other at the p<0.05 level.  
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burgdorferi, however, only the apoptotic Jurkat cell supernatant altered the 
percentage of neutrophils phagocytosing B. burgdorferi. (Figure 21B). We also 
wanted to determine the effect of AC supernatant on neutrophil migration to the 
chemoattractant LTB4. The percentage of migrated neutrophils to LTB4 was 
significantly decreased if first pre-incubated with apoptotic Jurkat cell supernatant 
(Figure 21C), a similar effect as using AC (Figure 7C). These data show AC 
supernatant can elicit a similar alteration of macrophage and some neutrophil 
effector functions as AC themselves. 
 
We previously have shown AC administration to B. burgdorferi-activated 
macrophages significantly increased their transcription of PPAR-γ in vitro and AC 
treatment in vivo increased PPAR-γ expression within the joints of B. burgdorferi-
infected mice (Figure 8). Therefore, we wanted to determine if the secretion of 
AC would be enough to elicit a similar increase in PPAR-γ as did AC 
administration. As shown in Figure 22, AC supernatant had little effect on PPAR-
γ transcription in unstimulated macrophages, however, the co-culture of AC 
supernatant in B. burgdorferi-stimulated macrophages caused significantly 
increased production of PPAR-γ, similar to AC. This shows the secreted products 
of the apoptotic cells alone are enough to elicit increased production of PPAR-γ 
in B. burgdorferi-activated macrophages.  
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Figure 22: AC and AC supernatant induction of PPAR-γ in BMDM. 
C3H BMDM were co-cultured with AC or ACS and/or B. burgdorferi for 24 hours, 
and PPAR-γ transcription was determined by real-time PCR. n=3 per group. Bars 
with different letters are significantly different from each other at the p<0.05 level. 
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Figure 23: In vitro quantification of cytokines in C3H BMDM co-cultured 
with apoptotic neutrophils and B. burgdorferi-activated apoptotic 
neutrophils. 
C3H BMDM were co-cultured with apoptotic neutrophils (AC) or AC given B. 
burgdorferi prior to apoptosis and B. burgdorferi for 24 hours. Cytokine levels of 
TNF-α (A), KC (B), and IL-10 (C) were quantified by ELISA. n=3 per group. Bars 
with different letters are significantly different from each other at the p<0.05 level. 
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B. burgdorferi and E. coli activated apoptotic neutrophils alter macrophage 
cytokine production in vitro 
To further our understanding of the role of AC in eliciting anti-inflammatory 
responses during B. burgdorferi-infection, we developed an in vitro system that  
would better replicate in vivo conditions. For these experiments, BMN were 
harvested and co-cultured with B. burgdorferi prior to undergoing apoptosis. After 
undergoing apoptosis, they were co-cultured with BMDM the same as AC were in 
previous experiments. We first determined how the activation of neutrophils prior 
to becoming apoptotic affected their ability to alter macrophage cytokine 
production. As shown in Figure 23, activating the neutrophils with B. burgdorferi 
caused significantly decreased levels of TNF-α (Figure 23A) and KC (Figure 23B) 
and increased IL-10 (Figure 23C) compared to B. burgdorferi-activated 
macrophages or macrophages given non-activated apoptotic neutrophils. While 
the activated neutrophils caused unstimulated macrophages higher cytokine 
production than using unstimulated apoptotic cells, the addition of B. burgdorferi 
to these macrophages caused no further increase in cytokine production.  
 
We then wanted to determine if this alteration of cytokines was a B. burgdorferi-
specific phenomenon or would the enhancement of the effects of bacterial 
activated neutrophils on macrophage cytokine production still happen if a 
different bacteria was used to activate the neutrophils. It has been previously 
shown that E. coli-activated apoptotic dendritic cells were able to downregulate 
immune responses once efferocytosed [57], so we used E. coli-activated  
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Figure 24: In vitro quantification of cytokines in C3H BMDM co-cultured 
with apoptotic neutrophils and E. coli-activated apoptotic neutrophils. 
C3H BMDM were co-cultured with apoptotic neutrophils (AC) or AC given E. coli 
prior to apoptosis and B. burgdorferi for 24 hours. Cytokine levels of TNF-α (A), 
KC (B), and IL-10 (C) were quantified by ELISA. n=3 per group. Bars with 
different letters are significantly different from each other at the p<0.05 level. 
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neutrophils to compare cytokine alteration in macrophages with B. burgdorferi-
activated neutrophils. To do this, we gave the neutrophils E. coli prior to 
neutrophil apoptosis, but the macrophages were still activated with B. 
burgdorferi. The E. coli-activated apoptotic neutrophils were able to elicit similar 
trends in macrophage cytokine alteration as the B. burgdorferi-activated 
apoptotic neutrophils (Figure 24A-C). These data show if neutrophils are first 
activated with either B. burgdorferi or E. coli prior to becoming apoptotic, they 
have an enhanced ability to alter macrophage cytokine production compared to 
using unstimulated apoptotic neutrophils. 
 
Activated apoptotic neutrophil supernatant alters macrophage cytokine 
production in vitro 
Our previous data suggested apoptotic Jurkat cell supernatant could elicit 
changes in macrophage cytokine production, so we determined how the 
supernatant of B. burgdorferi-activated apoptotic neutrophils would affect 
macrophage cytokine production. The secretions from the B. burgdorferi-
activated apoptotic neutrophils worked in a similar fashion as the activated 
apoptotic neutrophils in enhancing downregulation of TNF-α and KC and 
upregulation of IL-10 (Figure 25A-C) production by macrophages. Although KC 
production was not altered by the administration of apoptotic neutrophil 
supernatant, the use of B. burgdorferi-activated apoptotic neutrophil secreted 
products were able to significantly decrease the macrophage production of KC, 
just as well as B. burgdorferi-activated apoptotic neutrophils (Figure 25B).  
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Figure 25: In vitro quantification of cytokines in C3H BMDM co-cultured 
with apoptotic neutrophil supernatant and B. burgdorferi-activated 
apoptotic neutrophil supernatant. 
C3H BMDM were co-cultured with apoptotic neutrophil supernatant (ACS) or 
supernatant from AC given B. burgdorferi prior to apoptosis and B. burgdorferi for 
24 hours. Cytokine levels of TNF-α (A), KC (B), and IL-10 (C) were quantified by 
ELISA. n=3 per group. Bars with different letters are significantly different from 
each other at the p<0.05 level. 
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Additionally, the supernatant from apoptotic neutrophils contributed to enhanced 
IL-10 production (Figure 25C), a different phenotype than what was seen with the  
apoptotic Jurkat cells (Figure 23C), showcasing there might be different products 
produced by apoptotic Jurkat cells, induced via the extrinsic apoptosis pathway 
of CD95, compared to apoptotic BMN, induced mainly by intrinsic apoptosis. This 
shows even the secreted products of activated apoptotic neutrophils have an 
enhanced ability to alter macrophage cytokine production, just as well as the 
activated apoptotic neutrophils themselves.  
 
B. burgdorferi-activated apoptotic neutrophils have altered cytokine 
production 
Activated apoptotic neutrophils can alter macrophage cytokine production, 
however, we have not determined if cytokine production from the apoptotic 
neutrophils was altered when activated with B. burgdorferi prior to induction of 
apoptosis. As measured by Luminex, the cytokines KC, IL-10, and IL-6 were 
significantly higher in the B. burgdorferi-activated apoptotic neutrophils compared 
to unstimulated apoptotic neutrophils (Figure 26A, 26C, and 26E) with no change 
in MCP-1 levels (Figure 26D). Additionally, the only cytokine measured that was 
significantly decreased in the activated apoptotic neutrophils was TNF-α (Figure 
26B). Although KC production was significantly increased in the activated 
apoptotic neutrophils, this did not translate to increased KC production in B. 
burgdorferi co-cultured macrophages (Figure 23B). This data shows even though 
activated apoptotic neutrophils make higher levels of anti-inflammatory cytokines  
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Figure 26: In vitro quantification of apoptotic neutrophil and B. burgdorferi-
activated apoptotic neutrophil supernatant. 
C3H BMN were co-cultured with (ActAC) or without (AC) B. burgdorferi prior to 
apoptosis for 24 hours. Cytokine levels in the supernatant of KC (A), TNF-α (B), 
IL-10 (C), MCP-1 (D) and IL-6 (E) were quantified by Luminex Assay. n=2 per 
group. Bars with different letters are significantly different from each other at the 
p<0.05 level. 
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like IL-10, they also produce significantly higher levels of pro-inflammatory 
cytokines, however this does not contribute to increased inflammatory cytokine 
production by macrophages (Figure 23). Additionally, the only cytokine measured 
which decreased in the activated apoptotic neutrophils was TNF-α, suggesting 
TNF-α regulated inflammatory pathways may be causing the effect of the 
activated apoptotic neutrophils.  
 
B. burgdorferi apoptotic neutrophils are efferocytosed at the same rate as 
unstimulated neutrophils 
We have shown AC can downregulate responses in both macrophages and 
neutrophils (Figure 7) but have yet to determine how activated apoptotic 
neutrophils affect these functions. We next wanted to determine if activated 
apoptotic neutrophils were phagocytosed by macrophages at a different rate than 
unstimulated apoptotic neutrophils. As shown in Figure 27, the same percentage 
of macrophages had efferocytosed unstimulated apoptotic neutrophils and B. 
burgdorferi-activated apoptotic neutrophils. This shows even though activated 
apoptotic neutrophils are efferocytosed at the same rate as unstimulated 
apoptotic neutrophils, they still have a greater impact on macrophage cytokine 
production.  
 
Discussion 
While we know the clearance of AC can downregulate immune responses, 
determining what components of the AC are needed to elicit these responses will  
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Figure 27: Effect of B. burgdorferi-activated apoptotic neutrophils on 
macrophage efferocytosis. 
C3H BMDM were given CFSE-labeled apoptotic neutrophils cells (AC) or 
neutrophils activated with B. burgdorferi prior to apoptosis (ActAC) for 4 hours. 
The percentage of macrophages containing AC was determined by flow 
cytometry. n=3 per group. Bars with different letters are significantly different 
from each other at the p<0.05 level.  
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aid in a better understanding of how AC function during inflammation resolution. 
Some groups have used PS coated beads or liposomes in lieu of AC [153, 154], 
however, others have shown AC can secrete factors that play a role in the down-
regulation of immune responses [150, 151]. This shows not just the surface 
exposure of PS should be used to replicate the presence of AC, because AC are 
actively making and secreting cytokines, eicosanoids, and other factors as well.  
 
We therefore wanted to determine how the secretion of AC affected macrophage 
and neutrophil functions in vitro when co-cultured with B. burgdorferi. As shown 
here, the secretions of the apoptotic Jurkat cells were able to alter macrophage 
production of TNF-α as well as the apoptotic cells themselves, however the other 
cytokines measured, KC and IL-10, were not affected. This was different from 
using the supernatants of the apoptotic neutrophils, in which IL-10 was also 
altered. The discrepancies between the two types of apoptotic cell supernatant 
suggests apoptotic Jurkat cells and apoptotic BMN may secrete different factors. 
Additionally, macrophage and neutrophil phagocytosis of B. burgdorferi and 
neutrophil migration was significantly reduced when given the AC secretions. 
Also, the pro-resolution transcription factor PPAR-γ was also significantly 
increased in macrophages treated with the AC supernatant alone. This data 
suggests cells may not require the actual uptake of AC for their immune 
responses to be down-regulated by AC but may be influenced by AC in the local 
environment. 
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We also wanted to determine what effects activation of neutrophils prior to their 
apoptosis would have on their ability to alter macrophage functions. The 
administration of both B. burgdorferi- and E. coli-activated apoptotic neutrophils 
significantly decreased pro-inflammatory and increased anti-inflammatory 
cytokines much greater than using unstimulated apoptotic neutrophils. The 
supernatant of the B. burgdorferi-activated apoptotic neutrophils also was able to 
elicit a similar response. However, this increased ability to alter macrophage 
function was not due to decreased pro-inflammatory cytokine production by the 
activated apoptotic neutrophils, as they produced significantly higher levels of 
both pro- and anti-inflammatory cytokines compared to unstimulated apoptotic 
neutrophils of the cytokines we measured. The only cytokine measured that was 
significantly lower in the activated apoptotic neutrophils was TNF-α, suggesting 
TNF-α down-regulating pathways may explain why the activated apoptotic 
neutrophils elicit a much stronger alteration in cytokines by the macrophages. 
Additionally, other cytokines we did not measure may be playing a role as well. 
We have yet to measure any lipid mediators to determine if the lipid production 
profile differs in the activated apoptotic neutrophils, but considering apoptotic 
cells are known to produce anti-inflammatory PGE2, it would be interesting to see 
if activated apoptotic neutrophils have a much different lipid production profile 
compared to apoptotic neutrophils. Additionally, activated apoptotic neutrophils 
were efferocytosed at the same rate as unstimulated neutrophils, showing the 
rate of efferocytosis was not contributing to this increased function of the 
activated apoptotic neutrophils. This set of data showcases the importance of 
 90 | P a g e  
 
how a further understanding of the mechanisms apoptotic cells are needed to be 
able to elicit a down-regulation of pro-inflammatory mediators and promote 
inflammation resolution. A further understanding of this process will aid in our 
ability to utilize these anti-inflammatory pathways as therapeutic targets.  
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Chapter 6 
The Role of Prostaglandin E2 during Lyme Arthritis Resolution  
 
Introduction 
Prostaglandins are cyclooxygenase (COX) derived eicosanoids that play various 
signaling roles throughout the inflammatory response. The prostaglandin PGE2 is 
metabolized from arachidonic acid by COX-1 or COX-2 to PGH2, which is then 
processed by PGE synthase-1 (mPGES-1) to PGE2 [155]. While PGE2 is 
traditionally thought of as pro-inflammatory, as it is thought to be a primary driver 
of rheumatoid arthritis pathology, recent literature suggests it can also be anti-
inflammatory and promote resolution [156]. Dying cells release PGE2 to function 
as an inhibitory DAMP and aid in downregulating the pro-inflammatory response 
[151]. The pro-inflammatory or pro-resolution function of PGE2 depends on which 
of the four E-prostinoid (EP) receptors it signals through. Activation through the 
EP1 or EP3 receptor increases intracellular calcium and decreases intracellular 
cAMP, respectively, which contributes to inflammation [157]. Signaling through 
EP2 or EP4 results in increased intracellular cAMP to inhibit the formation of the 
pro-inflammatory Leukotrienes and also to promote the production of the 12/15 
lipoxygenase (12/15-LO) product lipoxin A4 [158]. Non-steroidal anti-inflammatory 
drugs, such as ibuprofen, are COX inhibitors, and these prevent the production of 
PGE2. While the use of these therapies might alleviate the symptoms of arthritis 
associated with pro-inflammatory PGE2 signaling, including pain and swelling, 
they may prolong the inflammatory response. 
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Our lab has previously used a lipidomics approach to arthritis-susceptible C3H 
mice exhibit an increase of PGE2 production within the joints during times of 
arthritis induction, 7 to 14 days pi, and also during arthritis resolution, 28 days pi 
[108]. This dual spike in PGE2 production points to a role for PGE2 in both 
arthritis induction and resolution. Additional studies from our lab using COX-2-/- 
mice have shown that in the absence of prostaglandin production, mice fail to 
resolve their arthritis, characterized by increased cellular infiltrate, as determined 
by histologic analysis, during and after resolution [104]. This may be due to the 
role of PGE2 in switching eicosanoid production from pro-inflammatory 5-LO, to 
pro-resolving 12/15-LO products. However, the use of Cox-2-/- mice not only 
prevented PGE2 production, but the production of other prostaglandins as well. 
For these studies, we wanted to determine the specific role of PGE2 during Lyme 
arthritis resolution and determine its role during efferocytosis. 
 
Results 
Macrophages produce PGE2 in response to AC and AC produce PGE2 in 
vitro 
Previously, we have shown the administration of AC to B. burgdorferi-activated 
macrophages altered macrophage cytokine production to a more anti-
inflammatory state (Figure 5), therefore, we first investigated how the  
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Figure 28: In vitro quantification of PGE2 in WT and Cox-2-/- BMDM 
supernatant co-cultured with apoptotic Jurkat cells. 
C3H WT (A) or C3H Cox-2-/- (B) were co-cultured with apoptotic Jurkat cells and 
B. burgdorferi for 24 hours, and PGE2 was quantified by EIA. n=3 per group. Bars 
with different letters are significantly different from each other at the P<0.05 level.  
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administration of AC altered macrophage production of PGE2. As shown in 
Figure 28A, the macrophages receiving both B. burgdorferi and AC had 
significantly increased levels of PGE2 production compared to macrophages co-
culture with B. burgdorferi alone. Additionally, Cox-2-/- macrophages, which are 
deficient in their ability to produce PGE2, still have levels of PGE2 when given AC 
(Figure 28B), confirming the results of others that AC release PGE2 [151]. These 
data show macrophages make increased amounts of PGE2 in the presence of 
AC, and that AC themselves can also produce PGE2. 
 
mPGES-1-/- mice have decreased swelling and increased cellular infiltrate 
during inflammation resolution 
The apoptosis of both neutrophils and macrophages, and the efferocytosis of 
these cells is an important mechanism mediating Lyme arthritis resolution. Since 
PGE2 appears to have an anti-inflammatory role in this model, we next 
determined how inflammation resolution is impacted within the ankle joints during 
B. burgdorferi infection in the absence of PGE2. By using mPGES-1-/- mice, that 
are unable to produce PGE2, we found mPGES-1-/- mice had significantly 
decreased ankle swelling throughout infection (Figure 29). This shows edema 
reduction in these mice, however, ankle swelling does not always correlate with 
the underlying inflammation. 
 
To further our understanding of the role of PGE2 during inflammation resolution, 
we determined how neutrophil and macrophage recruitment to the joints, and 
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Figure 29: Ankle swelling in B. burgdorferi-infected WT and mPGES-1-/- 
mice. 
C3H WT and mPGES-1-/- mice were infected with 1x105 B. burgdorferi, and ankle 
swelling was monitored weekly   
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how the apoptosis of these cells was impacted in the absence of PGE2.  
Using flow cytometry, neutrophil and macrophage numbers and the percentage 
of apoptotic neutrophils and macrophages were evaluated in B. burgdorferi-
infected mice during inflammation resolution. As shown in Figure 30, the number 
of neutrophils in the ankle joints was reduced at day 21 pi (Figure 30A) in the 
mPGES-1-/- mice compared to WT, however neutrophil numbers increased by 
day 28 pi (Figure 30B), and the number of neutrophils returned to WT levels on 
day 35 pi (Figure 30C). Additionally, there was no different in the percentage of 
apoptotic neutrophils between mPGES-1-/- and WT mice (Figure 30D-F) at any 
timepoints, suggesting the number of live neutrophils was always in a similar 
ratio to apoptotic neutrophils in both strains.  
 
While the number of macrophages was significantly lower in the mPGES-1-/- mice 
at day 21 pi (Figure 31A) with the same percentage of apoptotic macrophages 
(Figure 31D), there was a significant influx in the number of macrophages in the 
mPGES-1-/- mice compared to WT at both 28 (Figure 31B) and 35 (Figure 31C) 
days pi. This influx in macrophage number was also accompanied by a 
significant reduction in the percentage of apoptotic macrophages at days 28 
(Figure 31E) and 35 (Figure 31F) pi. The data suggests while ankle swelling is 
reduced in the mPGES-1-/- mice, the mice have increased cellular infiltrate, 
primarily non-apoptotic macrophages, during the resolution of inflammation, 
resulting in a prolonged inflammatory response. This increase in macrophages 
with fewer apoptotic macrophages could be contributing to the inflammatory  
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Figure 30: Quantification of neutrophils and apoptotic neutrophils within B. 
burgdorferi-infected ankle joints in C3H WT and mPGES-1-/- mice. 
Mice were infected with 1x105 B. burgdorferi and sacrificed at indicated days for 
flowy cytometry analysis of joint inflammatory cells. Total number of neutrophils 
(A-C) and the percentages of cleaved-caspase 3+ neutrophils (D-F) of total 
CD45.2+ inflammatory cells were evaluated on 21, 28, and 35 days pi. n=4 per 
group. Bars with different letters are significantly different from others at the 
p<0.05 level. 
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Figure 31: Quantification of macrophages and apoptotic macrophages 
within B. burgdorferi-infected ankle joints in C3H WT and mPGES-1-/- mice. 
Mice were infected with 1x105 B. burgdorferi and sacrificed at indicated days for 
flowy cytometry analysis of joint inflammatory cells. Total number of 
macrophages (A-C) and the percentages of cleaved-caspase 3+ macrophages 
(D-F) of total CD45.2+ inflammatory cells were evaluated on 21, 28, and 35 days 
pi. n=4 per group. Bars with different letters are significantly different from others 
at the p<0.05 level. 
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response and delaying inflammation resolution in the absence of PGE2. This 
same increase of cellular infiltrate was shown in the COX-2-/- mice [104], 
suggesting the reason for the inability for those mice to undergo inflammation 
resolution may be due to lack of PGE2 signaling. 
 
mPGES-1-/- macrophages have altered responses to apoptotic neutrophils 
in vitro 
To investigate the impact of the increased number of macrophages in the 
mPGES-1-/- mice during B. burgdorferi infection, we determined if PGE2 plays a 
role in macrophage cytokine production in the presence of apoptotic neutrophils. 
We have previously shown apoptotic neutrophils can alter macrophage cytokine 
production when in the presence of B. burgdorferi (Figure 6), and this change in 
macrophage phenotype can aid in the down-regulation of inflammatory 
responses. As shown in Figure 32A-C, both WT and mPGES-1-/- apoptotic 
neutrophils can cause a similar alteration of macrophage cytokine production in 
WT macrophages. However, both WT and mPGES-1-/- apoptotic neutrophils 
were unable to alter cytokine production for TNF-α (Figure 32D) KC (Figure 32E), 
or IL-10 (Figure 32F). This suggests that apoptotic cells are only able to induce 
an alteration in cytokine production if the macrophage can make PGE2. While 
apoptotic cells can make PGE2 (Figure 28B), macrophage production of PGE2 is 
needed to decrease pro-inflammatory and increase anti-inflammatory cytokine 
production in response to apoptotic neutrophils. 
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Figure 32: In vitro quantification of cytokines in C3H WT and mPGES-1-/- 
BMDM supernatant co-cultured with WT or mPGES-1-/- apoptotic 
neutrophils. 
C3H WT (A-C) and mPGES-1-/- (D-F) BMDM were co-cultured with either WT or 
mPGES-1-/- apoptotic neutrophils and B. burgdorferi for 24 hours, and cytokine 
levels of TNF-α (A,D), KC (B,E), and IL-10 (C,F) were quantified by ELISA. n=3 
per group. Bars with different letters are significantly different from each other at 
the p<0.05 level.  
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The efferocytosis of apoptotic neutrophils by phagocytic cells aids in the down-
regulation of inflammation and increases PPAR-γ transcription during B. 
burgdorferi infection. Therefore, we wanted to determine if efferocytosis of 
apoptotic neutrophils or PPAR-γ increase by apoptotic neutrophils would change 
without PGE2. There was no difference in efferocytosis in WT macrophages 
engulfing either WT or mPGES-1-/- apoptotic neutrophils (Figure 33), however 
mPGES-1-/- macrophages had significantly decreased efferocytosis of both WT 
and mPGES-1-/- apoptotic neutrophils. This suggests that macrophages unable to 
make PGE2 have a defect in the efferocytosis of apoptotic neutrophils.  
 
PPAR-γ transcription is upregulated in the presence of apoptotic neutrophils and 
plays an important role during inflammation resolution. As shown in Figure 34, 
transcription of PPAR-γ was significantly increased in B. burgdorferi co-cultured 
macrophages also given either WT or mPGES-1-/- apoptotic neutrophils. 
mPGES-1-/- macrophages had similar levels of PPAR-γ transcripts in both B. 
burgdorferi co-cultured macrophages and also those given either WT or mPGES-
1-/- apoptotic neutrophils. The mPGES-1-/- macrophages did not have enhanced 
PPAR-γ transcription with the administration of apoptotic neutrophils, unlike WT 
macrophages. These data provide further evidence that macrophages need 
autocrine PGE2 signaling for apoptotic neutrophils to stimulate inflammation 
resolution. 
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Figure 33: C3H WT and mPGES-1-/- BMDM efferocytosis of WT and mPGES-
1-/- apoptotic neutrophils. 
C3H WT or mPGES-1-/- BMDM were given either CFSE-labeled WT or mPGES-
1-/- apoptotic neutrophils at a 2:1 concentration for 4 hours. The percentage of 
macrophages containing apoptotic neutrophils was determined by flow 
cytometry. n=3 per group. Bars with different letters are significantly different 
from each other at the p<0.05 level. 
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Figure 34: C3H WT and mPGES-1-/- apoptotic neutrophil induction of PPAR-
γ in WT and mPGES-1-/- BMDM. 
C3H WT and mPGES-1-/- were co-cultured with either WT or mPGES-1-/- 
apoptotic neutrophils and/or B. burgdorferi for 24 hours. PPAR-γ transcription 
was determined by real-time PCR. n=3 per group. Bars with different letters are 
significantly different from each other at the p<0.05 level. 
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Discussion 
 While we have shown apoptotic cell clearance is important during inflammation 
resolution in Lyme arthritis, we are still trying to determine the mechanisms 
involved and the mediators involved. Eicosanoid pathways are prevalent in the 
regulation of inflammatory responses, therefore we wanted to determine the role 
of PGE2, an important lipid mediator in other inflammatory models, during Lyme 
arthritis. We show here that while apoptotic cells are able to produce PGE2 as 
previously described, PGE2 production by macrophages is essential in their 
response to apoptotic neutrophils. mPGES-1-/- mice had decreased swelling 
throughout infection compared to WT mice, however, mPGES-1-/- mice had 
increased inflammatory infiltrate during inflammation resolution. Because of the 
dual signaling role of PGE2, this may explain why decreased swelling was noted 
in the mPGES-1-/- mice, due to the fact the pro-inflammatory form of PGE2 
signaling through EP1 or EP3 did not occur, but the consequences of the inability 
to signal anti-inflammatory PGE2 through EP2 or EP4 also affected these mice. 
Additionally, pro-inflammatory PGE2 production may also be important for 
resolution, as inhibition of COX-2 in B. burgdorferi-infected mice early in infection 
also resulted in exacerbated cellular infiltrate during resolution [104].  
 
The increased cellular infiltrate within the joints of mPGES-1-/- mice was from 
macrophages, rather than neutrophils as we have shown in BLT1-/- mice. 
Additionally, a significantly lower percentage of these macrophages were 
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apoptotic, emphasizing an imbalance in the ratio of live cells to apoptotic cells. 
This suggests the macrophages may have increased recruitment and are living 
longer in B. burgdorferi-infected mPGES-1-/- mice compared to WT during the 
resolution stages. Because macrophages seem to be the cell out of balance 
during resolution in the absence of PGE2, we wanted to then characterize 
macrophage function in respects to their interaction with apoptotic neutrophils. 
We show here that while WT and mPGES-1-/- apoptotic neutrophils are able to 
elicit similar changes in cytokine production in WT macrophages, as previously 
shown, mPGES-1-/- macrophages are not affected by either WT or mPGES-1-/- 
apoptotic neutrophils. Additionally, mPGES-1-/- mice have a defect in apoptotic 
neutrophil efferocytosis, and apoptotic neutrophils do not increase PPAR-γ 
production in macrophages. This shows apoptotic neutrophils are unable to elicit 
the downregulation of the immune response through pro-inflammatory cytokine 
repression and anti-inflammatory cytokine production in mPGES-1-/- 
macrophages. Further, efferocytosis, a major mechanism during inflammation 
resolution is defective in mPGES-1-/- macrophages, suggesting PGE2 production 
by macrophages is important in the downregulation of immune responses during 
an inflammation. Overall, these data show the importance of PGE2 during 
inflammation resolution and suggest macrophage, rather than neutrophil 
production of PGE2 is more important in the anti-inflammatory response.  
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Chapter 7 
Discussion 
 
Experimental Lyme arthritis in mice is caused by infection with the spirochete B. 
burgdorferi and causes chronic inflammation of the weight bearing joints. While 
much is known how inflammation is initiated through the over-recruitment of 
innate immune cells, there is little evidence for how resolution of inflammation is 
initiated in this disease. Because mice are able to resolve their arthritis during B. 
burgdorferi infection, unlike many other murine models of arthritis, such as the 
CIA model of rheumatoid arthritis, this provides an excellent model to determine 
the mechanisms of inflammation resolution.  
 
Apoptotic cell detection and administration 
While the clearance of AC, especially apoptotic neutrophils, was hypothesized to 
initiate inflammation resolution during Lyme arthritis, there was little evidence for 
the occurrence of this phenomenon in vivo [76]. We show the increase in both 
number and percentage of apoptotic neutrophils and macrophages correlates 
with decreased ankle swelling and inflammation resolution during Lyme arthritis 
(Figure 3). Additionally, we used cleaved-caspase 3+ as a marker for apoptosis. 
Previously, it was common to use Annexin V, which stains phosphatidylserine, in 
conjunction with a viability dye, such as 7-AAD, to determine whether cells were 
live, in early apoptosis, in late apoptosis, or dead [159]. This issue with this 
method of AC detection is there is no way to determine the difference between 
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cells in late apoptosis (Annexin V+, 7-AAD+) and pyroptotic or necrotic cells, as 
the Annexin V cannot distinguish between phosphatidylserine on the cell surface 
as with AC vs inside the cell, as with all other cell types [159]. This causes 
difficulty when trying to characterize the form of death cells are undergoing 
during an inflammatory response. In addition, when using Annexin V, it can be 
difficult or impossible to stain for additional cellular markers, such as F4/80 for 
macrophages or Ly6G for neutrophils, to determine which cell type is apoptotic 
due to the binding requirements of Annexin V antibody. The use of Annexin V is 
more applicable in vitro in homogeneous cell populations, but using cleaved-
caspase 3 to determine apoptosis in vivo is the only way specific AC populations 
can be identified. Additionally, due to the fact cleaved-caspase 3 is an 
executioner caspase, it does not play a role in any other forms of cell death 
besides apoptosis, meaning it can better identify AC without also potentially 
staining pyroptotic or necrotic cells [133]. By defining the roles of apoptosis of 
neutrophils and macrophages and the efferocytosis of these cells during 
inflammation resolution, it will give better insight to how inflammation can be 
downregulated in chronic inflammatory diseases. 
 
Mechanisms of inflammation resolution with AC shown previously have been in 
autoimmune models, including lung fibrosis and rheumatoid arthritis [5, 77]. We 
show here AC play a role in inflammation resolution during Lyme arthritis, and 
similar to other chronic inflammatory models, are able to promote earlier arthritis 
resolution following their administration (Figure 4). Previously, others have shown 
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the treatment of mice with large quantities of AC (107 - 108) administered 
intraperitoneally (i.p.) or intravenously (i.v.) elicited a strong anti-inflammatory 
response in autoimmune arthritis models [77, 160, 161]. While this treatment 
strategy was able to downregulate inflammation, a large number of apoptotic 
cells was required for successful treatment. In our studies, we administered the 
AC locally in an attempt to reduce the number of AC needed to elicit a response. 
By using a more localized treatment, we were able to reduce the number of AC 
needed to elicit a response. Additionally, we were administering AC after arthritis 
induction as a therapeutic, rather than a preventative, which is more applicable to 
human Lyme arthritis treatment.  
 
Various other inflammatory models have given AC both therapeutically and 
prophylactically [5, 77]. However, during infectious diseases such as Lyme 
arthritis, some inflammation is needed for pathogen recognition and clearance by 
the immune system and differs from autoimmune models in which inflammation 
is not needed. We had to alter the time of AC administration compared to 
previously established models to avoid downregulating immune responses 
before bacterial clearance occurred. This is the first infectious disease model in 
which the administration of AC was able to initiate earlier inflammation resolution 
through the decreased recruitment of inflammatory cells. Additionally, the 
decreased recruitment of neutrophils by AC administration did not interfere with 
B. burgdorferi clearance, as both control and AC treated mice had similar 
bacterial loads throughout infection (Figure 4). Earlier administration of AC may 
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have reduced the host response to B. burgdorferi, due to AC downregulation of 
neutrophil and macrophage effector functions, including B. burgdorferi 
phagocytosis (Figure 7). Additionally, the similarity in B. burgdorferi loads while 
having differences in ankle swelling in the control mice compared to AC treated 
also demonstrates the point that the presence of B. burgdorferi does not drive the 
arthritis, but rather the over-recruitment of the innate immune cells in response to 
B. burgdorferi drives arthritis severity. This was supported previously when mice 
with exacerbated arthritis and ankle swelling had normal B. burgdorferi antibody 
production and pathogen clearance [3, 104].  
 
Localized administration of apoptotic cell-associated therapeutics 
While we were able to show AC treatment of macrophages resulted in significant 
alterations in cytokine production in vitro (Figure 5 & 6), we could not 
demonstrate this in vivo (Figure 4). This may be partially due to the limited 
number of AC that could be injected as a localized treatment, as only around 10 
µl can be injected into the tibio-tarsal synovial cavity. While increasing the 
number of AC per dose or increasing the number of doses may have had a much 
stronger effect in downregulating inflammation, we are trying to develop a cell-
free mechanism to promote arthritis resolution, rather than increasing AC 
treatment frequency. By promoting the similar effects as AC on inflammation 
resolution without the AC themselves would be a more appropriate treatment in 
humans for therapy of non-resolving inflammatory diseases.  
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The transcription factor PPAR-γ has been previously shown in other inflammatory 
models to be upregulated during AC administration [5], however, we show here 
administration of the PPAR-γ agonist rosiglitazone was able to elicit similar 
effects as the apoptotic cell treatment (Figure 11). Additionally, we show that like 
AC, rosiglitazone is able to decrease ankle swelling and decrease neutrophil 
recruitment to the joints. This is the first localized therapeutic that mimics the 
administration of AC in an inflammatory infectious disease, showcasing the 
potential for utilizing the apoptotic pathway mechanisms for human therapeutics. 
Because PPAR-γ performs several functions within the cell besides regulation of 
inflammation, including fatty acid storage and glucose metabolism, systemic 
administration is difficult without disrupting other cellular processes and functions 
[162]. Rosiglitazone was originally developed as a type 2 diabetes medication for 
its ability to regulate glucose metabolism, however, it also caused an increase in 
coronary artery disease prevalence during long term oral administration [163]. 
Instead of a systemic treatment with PPAR-γ, we tried to utilize a localized 
treatment, taking advantage of the fact the arthritis is localized to the ankle and 
knee joints and also to avoid long term complications. This local administration 
method of rosiglitazone is also more similar to our AC treatment regimen than in 
other models [5, 77].  
 
Ankle swelling and cellular infiltrate are not always correlated 
Ankle swelling is used to assess arthritis severity during Lyme arthritis, as well as 
other forms of arthritis, along with cellular infiltrates and levels of inflammation 
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within the joint as determined by histology and flow cytometry. However, ankle 
swelling does not always correlate to the underlying inflammation. As shown with 
the BLT1-/- mice, ankle swelling was only increased on day 35 pi (Figure 12), but 
these mice had exacerbated neutrophil infiltrate throughout inflammation 
resolution (Figure 13). Additionally, the mPGES-1-/- mice had decreased ankle 
swelling throughout B. burgdorferi infection compared to WT mice (Figure 29) 
however had increased macrophage infiltration during resolution compared to 
WT (Figure 31). These two examples demonstrate that while ankle swelling 
might indicate the size of the edema, it does not always correlate to the cellular 
infiltration and underlying inflammation within the joint, especially since PGE2 is a 
known regulator of edema [156].  
 
The role of LTB4 signaling and PGE2 production during inflammation 
resolution 
The mediators responsible for the induction of inflammation can vary among 
models and arthritis types. For example, the pro-inflammatory lipid LTB4 and its 
downstream signaling has been shown to play a role in the induction of 
rheumatoid arthritis. Mice deficient in 5-LO-activating protein (FLAP) had 
decreased disease onset in the collagen-induced arthritis model [124], and 
blocking BLT1 signaling with BLT1-/- mice resulted in complete protection from 
CIA development [164]. A similar phenomenon occurred in the K/BxN serum 
transfer model of rheumatoid arthritis, in which neutrophil recruitment through 
LTB4 signaling was required for disease [165].  
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However in contrast to the above studies, we show here blocking of BLT1 
signaling through the use of BLT1-/- mice resulted in exacerbated neutrophil 
infiltrate during resolution and caused prolonged inflammation (Figure 12 & 13). 
Although rheumatoid arthritis and Lyme arthritis are both chronic inflammatory 
diseases, they have different roles for the signaling of LTB4 through BLT1. Even 
though many of the mechanisms of disease pathogenesis may be similar, Lyme 
arthritis is an infectious arthritis and rheumatoid arthritis models try to recapitulate 
the onset of an autoimmune disease. Therefore, therapies need to be verified in 
various inflammatory models due to the potential for different roles of various 
mediators, because blocking of LTB4 signaling may aid in preventing rheumatoid 
arthritis development but causes exacerbated inflammation during Lyme arthritis 
and possibly other inflammatory diseases.  
 
The blocking of inflammation and inflammatory lipid signaling is a commonly 
used strategy for developing arthritis therapeutics. Many individuals frequently 
use ibuprofen, a COX inhibitor, to alleviate the unpleasant symptoms of arthritis, 
such as pain and swelling. However, the administration of these drugs may delay 
resolution and in turn prolong inflammation, as previously shown in COX-2-/- mice 
infected with B. burgdorferi [104]. Additionally, some of the pro-inflammatory 
lipids also have anti-inflammatory signaling ability as well. PGE2 is the main 
driver of inflammation during rheumatoid arthritis [166], however, it possibly has a 
both pro- and anti-inflammatory role during Lyme arthritis. PGE2 may be 
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responsible for arthritis induction, but it also plays a key role during resolution. 
Lipidomics in B. burgdorferi-infected mice showed increased PGE2 both during 
arthritis onset and resolution [108]. Additionally, mPGES-1-/- mice have 
decreased ankle swelling and cellular infiltrate early in B. burgdorferi infection, 
however, while their ankle swelling remains decreased (Figure 29), there are 
nearly four times as many infiltrating macrophages during the resolution stages 
(Figure 31). This increased infiltrate causes exacerbated arthritis within the joints 
and prolongs inflammation, even with decreased ankle swelling.  
 
LTB4 is a pro-inflammatory eicosanoid responsible for the recruitment of 
neutrophils. Blocking of LTB4 has been shown to prevent disease onset and 
severity in rheumatoid arthritis [164], but it also plays a role during resolution in 
Lyme arthritis. Without LTB4 signaling, BLT1-/- neutrophils are unable to 
downregulate cAMP, which prevents DISC complex formation (Figure 19). This 
decrease in DISC formation is responsible for decreased apoptosis and 
efferocytosis of apoptotic neutrophils and prolongs inflammation. Additionally, 
neutrophils can be recruited by other mechanisms besides LTB4. Even though 
BLT1-/- neutrophils do not migrate to LTB4 as well as WT neutrophils, they can 
still migrate to other chemo-attractants, such as KC during Lyme arthritis [100]. 
This shows there can be multiple ways cellular recruitment during an 
inflammatory response can occur and blocking one path of neutrophil recruitment 
does not always mean the ability to recruit neutrophils is completely lost. Also, 
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blocking the signaling of these pro-inflammatory mediators can have downstream 
consequences during the resolution phase as well.  
 
Eicosanoids play an important role during both arthritis induction and resolution, 
however, certain eicosanoids are required by specific cell types to perform these 
roles. It is important for neutrophils to be able to signal LTB4 through the BLT1 
receptor to be able to undergo efficient apoptosis and be efferocytosed by 
macrophages (Figure 15). Additionally, BLT1-/- macrophages were able to 
efferocytose WT apoptotic neutrophils at a similar rate as WT macrophages, 
showing BLT1 signaling on the macrophage is not critical for efferocytosis. 
However, both WT and BLT1-/- macrophages were unable to efficiently 
efferocytose BLT1-/- apoptotic neutrophils (Figure 15D), showing BLT1 signaling 
in neutrophils is important for efferocytosis. This suggests a defect in neutrophil 
signaling is likely responsible for the defect in inflammation resolution found in 
BLT1-/- mice infected with B. burgdorferi.  
 
One major finding of this work is that macrophage production of PGE2 is critical 
for their modulation by apoptotic neutrophils. Even though apoptotic neutrophils 
were able to make PGE2 [151] (Figure 28B), macrophage production of PGE2 
was required to signal the downregulation of cytokines in response to apoptotic 
neutrophils. WT and mPGES-1-/- apoptotic neutrophils were able to alter cytokine 
production of B. burgdorferi-activated WT macrophages, showing production of 
PGE2 by apoptotic neutrophils was not required, however, neither WT and 
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mPGES-1-/- apoptotic neutrophils were able to alter cytokine production in 
mPGES-1-/- macrophages (Figure 32). Additionally, WT macrophages could 
efferocytose WT and mPGES-1-/- apoptotic neutrophils at the same rate, but 
mPGES-1-/- macrophages were defective in efferocytosing either WT or mPGES-
1-/- apoptotic neutrophils (Figure 33). This demonstrates LTB4 and PGE2 act at 
different points in the apoptotic pathway to coordinate clearance of apoptotic 
cells, where BLT1 signaling is important for neutrophil apoptosis and 
macrophages require endogenous PGE2 to perform effector functions associated 
with apoptotic neutrophils. This defect in PGE2 production may also explain the 
exacerbated number of macrophages shown during inflammation resolution in 
mPGES-1-/- mice (Figure 31).  
 
Many eicosanoid pathway knockout mice have only been available for a limited 
time, so previously, others have utilized various inhibitors during in vitro cultures 
to determine the role of the eicosanoids [167]. While this gives a general idea of 
the role of the mediators being inhibited, it does not separate the role of the 
mediators in different cell types. As shown here, BLT1 signaling is needed for 
neutrophils, while PGE2 production is important for macrophages during 
apoptosis and efferocytosis. If inhibitors were used to determine these functions 
in vitro, it would have been impossible to determine which cell type was 
responsible for the defect, and it would be difficult to come to a mechanistic 
conclusion to explain the exacerbated cellular infiltrate and arthritis in both cases. 
The ability to tease apart differences in eicosanoid signaling requirements for the 
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different immune cell types will allow for a better understanding of the roles of the 
eicosanoids during inflammation resolution. 
 
The use of flow cytometry to identify and quantify cellular infiltrates within 
inflamed mouse joints is a relatively recent development [98, 112]. Prior to this, 
studies were done using only histological analysis of the H&E stained slides with 
severity scores provided by a blinded observer [2, 3]. When using flow cytometry 
to determine cellular populations of inflammatory cells within tissues, it is 
important to look at data in several different ways to fully understand what is 
occurring in vivo. We were able to determine the number of neutrophils and 
macrophages throughout B. burgdorferi infection within the ankle joints of mice. 
Using additional cellular markers, determining phenotypic differences between 
these cells was also possible. By using cleaved-caspase 3 antibody, we were 
able to determine the number of apoptotic neutrophils and macrophages within 
the inflamed joint. In addition, the percentage of these apoptotic cells was also 
determined, which gave a different perspective on the data. While BLT1-/- joints 
contained a similar number of apoptotic neutrophils as WT, they had a 
significantly decreased percentage of apoptotic cells due to the increase in the 
number of live neutrophils (Figure 13). If only the number of apoptotic cells had 
been assessed, we would have detected no difference between BLT1-/- and WT 
mice, however, when considering the total number of neutrophils provides 
additional information. Often the inflammatory response is based on the signals 
present and the quantity of these signals. Therefore the ratio of live to apoptotic 
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neutrophils and macrophages should be considered when assessing the 
mechanisms of inflammation resolution and the defects that can arise in 
knockout mice. 
 
LTB4 signals through two receptors, BLT1 and BLT2. BLT1 is the high affinity 
receptor, while BLT2 is the low affinity receptor, and LTB4 preferentially signals 
through BLT1 if both receptors are present [135]. For certain mechanisms, BLT2 
can substitute for the absence of BLT1, such as in macrophage phagocytosis of 
B. burgdorferi [134]. However, high concentrations of LTB4 were required for 
BLT2 to function similar to BLT1. We noted a similar phenomenon in which BLT1-
/- neutrophils were unable to migrate to LTB4, even though they have a functional 
BLT2 receptor (Figure 15C). This shows while LTB4 can signal through BLT2, it 
requires a higher concentration of LTB4. This shows while there might be multiple 
receptors for a signaling mediator, it does not always mean they signal and 
function in the same capacity under the same conditions as other receptors. 
 
Eicosanoids are produced through enzymatic reactions, and often the removal of 
an enzyme affects the synthesis of several mediators, rather than just one. For 
example, rofecoxib, marketed as Vioxx as an anti-inflammatory NSAID for 
osteoarthritis and acute pain conditions, inhibited COX-2. The drug was taken off 
the market five years later due to increased risks of heart attack and stroke 
associated with long-term usage [168]. The main mechanism proposed to explain 
these side effects was the suppression of prostacyclin, an anti-clotting agent in 
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the blood [169]. Because Vioxx specifically inhibited the COX-2 enzyme, 
prostacyclin production decreased in endothelial cells and led to problems with 
declumping and vasodilation [169]. In addition to these concerns, others have 
hypothesized cardiotoxicity may be associated with anhydride metabolites 
formed when Vioxx became ionized during physiological conditions [168]. This 
shows by blocking an enzyme like COX-2, that is responsible for the production 
of several lipid mediators, unintended side effects can result from trying to block 
inflammation. A similar phenomenon was previously shown during Lyme arthritis 
in the inhibition of both COX-2 and 5-LO enzymes [3, 104]. While inhibition of 
these enzyme was intended to prevent inflammation, it ultimately resulted in 
exacerbated and prolonged arthritis. 
 
Another important point to consider when working within enzymatic systems is 
substrate bioavailability. If an enzyme is removed from the system, its substrate 
may now be available for use by other enzymes and result in increased 
production of other mediators due. For example in mPGES-1-/- mice, other 
prostaglandins, including thromboxane B2, PGD2, PGF2α and 6-keto-PGF1α, were 
reported to be significantly elevated in stomach tissue during LPS-stimulation 
[170]. This demonstrates that even if a phenotype is seen in a knockout mouse, it 
does not necessarily mean the lack of that specific enzymatic product or 
signaling causes the phenotype. The increased production of other metabolites 
could also cause the change in phenotype. This could explain the alteration in 
phenotype seen in mPGES-1-/- macrophages in response to the apoptotic 
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neutrophils. These macrophages could be making increased amounts of other 
eicosanoids resulting in the inability of apoptotic neutrophils to alter their 
production of cytokines (Figure 32) and the defect in macrophages to detect 
apoptotic neutrophils for efferocytosis as well (Figure 33). 
 
Arachidonic acid is released from membrane stores by the action of 
phospholipase A2, which is readily available in the cytosol of cells. While most 
cells have the potential to produce the various derivatives of arachidonic acid, it 
does not mean their signaling receptors are expressed on every cell type in the 
same abundance as well. Both BLT1 and BLT2 signal in response to LTB4, 
however, their expression on cell types and ligand specificity is vastly different. 
BLT1 is mainly found only on leukocyte subsets, while BLT2 is more 
constitutively expressed on cells throughout the body [131]. Some cells may 
produce greater amounts of certain eicosanoids than others. Both neutrophils 
[151] and macrophages [171] are able to produce PGE2, however, macrophage 
production of PGE2 is much greater than that of neutrophils. These differences in 
expression of receptors and production of eicosanoids can explain why certain 
mediators are required by specific immune cells during the inflammatory 
response and also during resolution. 
 
Secreted factors of apoptotic cells 
The process of acquiring AC for both in vitro and in vivo is labor intensive. 
Inducing apoptosis in Jurkat cells or harvesting neutrophils and inducing 
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apoptosis requires planning to time everything correctly. Because of this, other 
groups have resorted to using either phosphatidylserine or phosphatidylserine 
coated liposomes instead of AC to study the effects of AC on inflammation. 
phosphatidylserine is used to replicate the main characteristic of AC, having 
phosphatidylserine located on the cell surface. While this may be a more 
convenient method, it does not take into account the other mediators AC produce 
when undergoing apoptosis. Here we show both apoptotic Jurkat cells (Figure 
20) and apoptotic neutrophils (Figure 25) secrete factors that can alter 
macrophage cytokine production. Additionally, secreted factors from apoptotic 
Jurkat cells were able to decrease macrophage phagocytosis of B. burgdorferi 
(Figure 21A) and suppress neutrophil migration to LTB4 (Figure 21C). This 
demonstrates that factors besides phosphatidylserine on the cell surface can 
alter cytokine production macrophages and effector functions of neutrophils and 
macrophages.  
 
While the use of phosphatidylserine may elicit responses, it does not take into 
account all of the secreted factors apoptotic cells produce. While it is known 
phosphatidylserine is an important characteristic of AC, we are still determining 
the role of other mediators, including actively secreted factors, that may 
contribute to the role these cells play during an inflammatory response. 
Additionally, some of these secreted factors may be responsible for or aid in the 
downregulation of inflammation, therefore, using AC is more biologically relevant 
than using phosphatidylserine alone. Apoptosis is a biologically active process, 
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meaning cells are undergoing physical changes and secreting various factors as 
apoptosis occurs, including cytokines and lipid mediators. Without these factors 
present, the full picture of how these cells are able to perform their anti-
inflammatory functions is incomplete. 
 
All AC have similar characteristics, but different sources of AC may secrete 
different factors. Because the cells themselves are removed from the equation by 
only utilizing AC supernatant, what is causing the alteration in immune cell 
function must be something they produce and secrete. Apoptotic Jurkat cell 
supernatant was only able to alter macrophage cytokine production of TNF-α and 
did not affect KC or IL-10 production (Figure 20). However, when apoptotic 
neutrophil secretions were used, they were able to alter both TNF-α and IL-10 
levels (Figure 25). This suggests differences between the mediators being 
secreted by apoptotic Jurkat cells and apoptotic neutrophils. The differences in 
these factors could potentially be cytokines or lipids, as we have shown apoptotic 
neutrophils can produce various cytokines (Figure 26) and PGE2 (Figure 28B). 
Cytokines can alter macrophage cytokine production and effector functions of 
both neutrophils and macrophages. Additionally, various inflammatory lipids are 
known to alter these functions in neutrophils and macrophages as well, so it 
seems plausible apoptotic Jurkat cells and apoptotic neutrophils may have 
different amounts of various secretory products. 
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We have shown the injection of apoptotic Jurkat cells into the ankle joints of B. 
burgdorferi-infected mice decreased ankle swelling and promoted resolution 
(Figure 4), but we have still not determined if the injection of apoptotic Jurkat cell 
or apoptotic neutrophil supernatant might elicit a similar effect. Since the ultimate 
goal for treatment associated with AC mechanisms is to develop a cell free 
therapeutic, determining the components in the AC supernatant responsible for 
the downregulation of inflammation could lead to another potential therapeutic 
approach. While the administration of cytokines would be fairly easy as they are 
administered during other diseases, treatment using lipid mediators might pose a 
problem. These often have a very short half-life in vivo, for example, PGE2 which 
has the half-life of only a few minutes [172], but others have modified these 
mediators to elicit their effects without such fast degradation [173].  
 
B. burgdorferi activated apoptotic neutrophils on macrophage functions in 
vitro 
Even though apoptotic Jurkat cells and apoptotic neutrophils were able to alter 
macrophage function in vitro, we wanted to better replicate in vivo conditions, as 
far as the timing of bacterial administration. During an infection, neutrophils are 
first recruited to the site of infection to phagocytose B. burgdorferi and then 
undergo apoptosis. This means apoptotic neutrophils in vivo are more likely to 
have phagocytosed B. burgdorferi prior to undergoing apoptosis and subsequent 
efferocytosis. By activating neutrophils with B. burgdorferi prior to apoptosis 
induction, this will better replicate the order which B. burgdorferi phagocytosis, 
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apoptosis, and efferocytosis normally occurs. As shown in this dissertation, this 
sequence of events results in an even more extreme alteration in cytokine 
production by macrophages (Figure 23) and was also true for E. coli-activated 
apoptotic neutrophils (Figure 24). This was the first example of activating 
neutrophils prior to apoptosis and then administering them to B. burgdorferi-co-
cultured macrophages.  
 
While we have shown the effects of using activated apoptotic neutrophils in vitro, 
we have not yet determined why these cells have much more enhanced effects 
over unstimulated apoptotic neutrophils. Since activated apoptotic neutrophil 
supernatant also causes this alteration (Figure 25), it is likely a secreted factor is 
responsible. One possibility could be an alteration in apoptotic neutrophil 
cytokine production. Neutrophils make cytokines in response to a bacterial 
encounter, just as macrophages do, however, they generally make much lower 
levels of cytokines. In addition, of the cytokines we measured from activated 
apoptotic neutrophils, both pro- and anti-inflammatory mediators were higher, 
except for TNF-α (Figure 26). While other cytokines could be responsible for their 
effects on macrophages, it seems activated apoptotic neutrophils make higher 
levels of most cytokines overall, making cytokines an unlikely contributor to 
macrophage cytokine production.  
 
Another probable contributor to this phenomenon is lipid mediators. Dendritic 
cells have enhanced production of PGE2 in response to efferocytosis of E. coli-
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infected macrophages, aiding in the downregulation of inflammation [57], and 
apoptotic Jurkat cells produce and enhance B. burgdorferi-co-cultured 
macrophage production of PGE2 as well (Figure 28). This means activated 
apoptotic neutrophils could produce enhanced PGE2 production in addition to 
other lipid mediators. Lipidomics analysis will be required on the apoptotic 
neutrophils and activated apoptotic neutrophils to determine what lipids are 
normally produced by apoptotic neutrophils and to determine if activated 
apoptotic neutrophils have an altered lipid production profile. There is still much 
to be done to fully understand the role of lipid mediators during apoptosis and 
efferocytosis.  
 
Apoptotic cells for therapeutic strategies 
Current therapeutic strategies for chronic inflammatory diseases mostly involves 
trying to suppress or prevent pro-inflammatory mediators. While this may 
temporarily alleviate the symptoms, it does not aid in inflammation resolution, 
meaning long-term therapeutics are often the only solution to these problems. As 
shown here, AC play a role during inflammation resolution, and their 
administration in B. burgdorferi-infected mice promotes earlier resolution. While 
the injection of AC promotes resolution, we sought to determine the mechanism 
as to why this phenomenon occurs to be able to develop a cell free therapeutic 
strategy. To do this, we needed to determine the mechanism by which this 
phenomenon associated with AC and the downregulation of inflammation 
occurred. Previously, others have shown AC promote PPAR-γ expression, which 
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aids in resolution during an inflammatory response [5, 77], however, we 
demonstrate a cell free mechanism in which we administered the PPAR-γ agonist 
rosiglitazone, in lieu of AC, which was shown to have a similar effect (Figure 11). 
We also showed supernatant from apoptotic Jurkat cells (Figure 20) and 
activated apoptotic neutrophils (Figure 25) were able to alter macrophage 
cytokine production similar to AC, showing another potential cell free therapeutic. 
Furthering our understanding of this mechanism of how AC promote 
inflammation resolution will lead to better therapeutics strategies to resolve 
inflammation, rather than trying to block the pro-inflammatory mediators involved, 
which may prolong inflammation. 
 
Conclusions 
The work shown in this thesis represents substantial progress in understanding 
the role of apoptosis and apoptotic cells on inflammation resolution during 
experimental Lyme arthritis. We show the localized administration of apoptotic 
Jurkat cells into the tibio-tarsal joints of B. burgdorferi-infected mice aids in 
inflammation resolution by increasing PPAR-γ activation. While others had shown 
the correlation between AC administration and PPAR-γ [5], this is the first 
example of this during a bacterial infection and the use of localized rosiglitazone 
administration. We also show the importance of inflammatory lipid mediator 
signaling of the eicosanoids LTB4 and PGE2. While LTB4 signaling through BLT1 
is required for neutrophil apoptosis and clearance, our data suggests 
macrophages need exogenous PGE2 production for efferocytosis of apoptotic 
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neutrophils. We also show the importance of using Jurkat cells and neutrophils 
as apoptotic cells instead of just phosphatidylserine, because these apoptotic 
cells are actively secreting cytokines and lipid mediators during their apoptosis, 
contributing to their role in the downregulation of inflammation. Utilizing activated 
apoptotic neutrophils, we were able to better replicate in vivo conditions, which 
enhanced the alteration of macrophage cytokine production, showing another 
aspect of this phenomenon that requires further understanding. Future studies 
will focus on why macrophages require production of PGE2 for cytokine alteration 
by apoptotic neutrophils and efferocytosis. In addition, we will determine the 
secretory components of both apoptotic neutrophils and activated apoptotic 
neutrophils to determine what component in their supernatant is resulting in their 
anti-inflammatory effects on macrophages and to determine why activated 
apoptotic neutrophils have an enhanced ability over unstimulated apoptotic 
neutrophils. 
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Appendix I 
 
AVG ΔCt 
(Ct(GOI) - Ave Ct (HKG)) 
2^-ΔCt 
Fold Up- or Down-
Regulation 
Symbol 
Test 
Group 
Control 
Group 
Test 
Group 
Control 
Group 
Test Group 
/Control Group 
Abl1 7.10 5.83 7.3E-03 1.8E-02 -2.42 
Aifm1 6.55 6.05 1.1E-02 1.5E-02 -1.41 
Akt1 5.82 5.54 1.8E-02 2.1E-02 -1.21 
Anxa5 5.59 5.01 2.1E-02 3.1E-02 -1.50 
Apaf1 6.74 6.04 9.3E-03 1.5E-02 -1.63 
Api5 5.13 5.00 2.9E-02 3.1E-02 -1.09 
Atf5 6.41 5.63 1.2E-02 2.0E-02 -1.71 
Bad 6.18 6.00 1.4E-02 1.6E-02 -1.14 
Bag1 6.39 6.31 1.2E-02 1.3E-02 -1.06 
Bag3 5.84 5.29 1.7E-02 2.6E-02 -1.46 
Bak1 6.51 6.95 1.1E-02 8.1E-03 1.36 
Bax 5.14 4.09 2.8E-02 5.9E-02 -2.07 
Bcl10 4.89 4.65 3.4E-02 4.0E-02 -1.18 
Bcl2 6.30 5.73 1.3E-02 1.9E-02 -1.49 
Bcl2a1a 6.14 5.03 1.4E-02 3.1E-02 -2.16 
Bcl2l1 3.71 2.38 7.6E-02 1.9E-01 -2.52 
Bcl2l10 7.15 6.86 7.0E-03 8.6E-03 -1.22 
Bcl2l11 6.35 6.49 1.2E-02 1.1E-02 1.10 
Bcl2l2 7.22 6.80 6.7E-03 9.0E-03 -1.34 
Bid 6.78 6.53 9.1E-03 1.1E-02 -1.19 
Birc2 5.83 5.05 1.8E-02 3.0E-02 -1.72 
Birc3 5.97 5.61 1.6E-02 2.0E-02 -1.28 
Birc5 4.69 4.41 3.9E-02 4.7E-02 -1.21 
Bnip2 5.62 4.91 2.0E-02 3.3E-02 -1.64 
Bnip3 4.28 4.28 5.1E-02 5.1E-02 1.00 
Bnip3l 4.32 4.22 5.0E-02 5.4E-02 -1.08 
Bok 3.95 3.14 6.5E-02 1.1E-01 -1.75 
Card10 4.75 3.72 3.7E-02 7.6E-02 -2.04 
Casp1 6.88 6.15 8.5E-03 1.4E-02 -1.65 
Casp12 5.39 4.98 2.4E-02 3.2E-02 -1.33 
Casp14 3.88 2.77 6.8E-02 1.5E-01 -2.16 
Casp2 5.44 4.84 2.3E-02 3.5E-02 -1.52 
Casp3 4.37 3.32 4.8E-02 1.0E-01 -2.06 
Casp4 7.07 7.17 7.4E-03 6.9E-03 1.07 
Casp6 6.61 6.12 1.0E-02 1.4E-02 -1.41 
Casp7 5.46 4.70 2.3E-02 3.8E-02 -1.69 
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Casp8 6.43 6.08 1.2E-02 1.5E-02 -1.27 
Casp9 6.08 5.58 1.5E-02 2.1E-02 -1.41 
Cd40 5.96 6.16 1.6E-02 1.4E-02 1.14 
Cd40lg 7.03 6.33 7.6E-03 1.2E-02 -1.63 
Cd70 6.44 6.54 1.2E-02 1.1E-02 1.07 
Cflar 5.16 5.01 2.8E-02 3.1E-02 -1.11 
Cidea 4.49 4.49 4.4E-02 4.4E-02 -1.00 
Cideb 5.29 4.59 2.5E-02 4.2E-02 -1.63 
Cradd 5.55 4.53 2.1E-02 4.3E-02 -2.03 
Dad1 5.14 4.17 2.8E-02 5.6E-02 -1.97 
Dapk1 6.64 6.21 1.0E-02 1.4E-02 -1.35 
Dffa 7.25 7.41 6.6E-03 5.9E-03 1.11 
Dffb 6.58 6.06 1.0E-02 1.5E-02 -1.44 
Diablo 6.04 5.83 1.5E-02 1.8E-02 -1.16 
Fadd 4.50 3.24 4.4E-02 1.1E-01 -2.39 
Fas 5.40 4.21 2.4E-02 5.4E-02 -2.28 
Fasl 5.35 5.24 2.4E-02 2.6E-02 -1.08 
Gadd45a 7.40 7.12 5.9E-03 7.2E-03 -1.22 
Igf1r 3.87 2.61 6.8E-02 1.6E-01 -2.40 
Il10 6.72 6.43 9.5E-03 1.2E-02 -1.22 
Lhx4 5.86 5.77 1.7E-02 1.8E-02 -1.07 
Ltbr 4.72 3.68 3.8E-02 7.8E-02 -2.06 
Mapk1 5.99 5.95 1.6E-02 1.6E-02 -1.02 
Mcl1 6.80 6.65 9.0E-03 1.0E-02 -1.11 
Naip1 6.44 6.59 1.2E-02 1.0E-02 1.11 
Naip2 6.38 5.83 1.2E-02 1.8E-02 -1.47 
Nfkb1 6.24 5.87 1.3E-02 1.7E-02 -1.29 
Nme5 5.52 5.23 2.2E-02 2.7E-02 -1.23 
Nod1 4.99 4.02 3.1E-02 6.2E-02 -1.97 
Nol3 5.77 4.83 1.8E-02 3.5E-02 -1.92 
Polb 6.59 6.11 1.0E-02 1.5E-02 -1.40 
Prdx2 4.98 4.39 3.2E-02 4.8E-02 -1.50 
Pycard 7.31 7.89 6.3E-03 4.2E-03 1.49 
Ripk1 7.03 6.70 7.6E-03 9.6E-03 -1.27 
Tnf 6.46 6.86 1.1E-02 8.6E-03 1.32 
Tnfrsf10b 4.95 5.28 3.2E-02 2.6E-02 1.25 
Tnfrsf11b 6.29 5.67 1.3E-02 2.0E-02 -1.54 
Tnfrsf1a 6.16 5.77 1.4E-02 1.8E-02 -1.31 
Tnfsf10 5.43 4.57 2.3E-02 4.2E-02 -1.82 
Tnfsf12 6.51 6.23 1.1E-02 1.3E-02 -1.21 
Traf1 4.87 3.83 3.4E-02 7.0E-02 -2.06 
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Traf2 6.42 6.81 1.2E-02 8.9E-03 1.31 
Traf3 6.73 6.41 9.4E-03 1.2E-02 -1.25 
Trp53 4.62 3.30 4.1E-02 1.0E-01 -2.50 
Trp53bp2 6.66 6.55 9.9E-03 1.1E-02 -1.08 
Trp63 6.22 5.36 1.3E-02 2.4E-02 -1.82 
Trp73 6.78 6.63 9.1E-03 1.0E-02 -1.11 
Xiap 7.01 6.67 7.8E-03 9.8E-03 -1.27 
Actb 4.62 4.17 4.1E-02 5.6E-02 -1.37 
B2m 2.97 1.60 1.3E-01 3.3E-01 -2.58 
Gapdh 0.00 0.00 1.0E+00 1.0E+00 -1.00 
Gusb 5.31 4.47 2.5E-02 4.5E-02 -1.79 
Hsp90ab1 2.84 1.73 1.4E-01 3.0E-01 -2.16 
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